<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81070</article-id><article-id pub-id-type="doi">10.7554/eLife.81070</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>The forgotten people: Hepatitis B virus (HBV) infection as a priority for the inclusion health agenda</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-284558"><name><surname>Martyn</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284546"><name><surname>Eisen</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284547"><name><surname>Longley</surname><given-names>Nicky</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-284548"><name><surname>Harris</surname><given-names>Philippa</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284549"><name><surname>Surey</surname><given-names>Julian</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284550"><name><surname>Norman</surname><given-names>James</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284551"><name><surname>Brown</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-284552"><name><surname>Sultan</surname><given-names>Binta</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284553"><name><surname>Maponga</surname><given-names>Tongai G</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284554"><name><surname>Iwuji</surname><given-names>Collins</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-284555"><name><surname>Flanagan</surname><given-names>Stuart</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-284556"><name><surname>Ghosh</surname><given-names>Indrajit</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-284557"><name><surname>Story</surname><given-names>Alistair</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-284545"><name><surname>Matthews</surname><given-names>Philippa C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4036-4269</contrib-id><email>philippa.matthews@crick.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf6"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tnbqb63</institution-id><institution>The Francis Crick Institute</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00a0jsq62</institution-id><institution>London School of Hygiene &amp; Tropical Medicine</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00fdbgx35</institution-id><institution>Hospital for Tropical Diseases, Division of Infection, University College London Hospitals NHS Foundation Trust</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042fqyp44</institution-id><institution>Department of Infectious Diseases, University College London Hospitals NHS Foundation Trust</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02wnqcb97</institution-id><institution>Find &amp; Treat Service, Division of Infection, University College London Hospitals NHS Foundation Trust</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jx3x895</institution-id><institution>Institute of Global Health, University College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cby8j38</institution-id><institution>Universidad Autonoma de Madrid, Ciudad Universitaria de Cantoblanco</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/056hsfz11</institution-id><institution>Mortimer Market Centre, Central and North London NHS Foundation Trust</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05bk57929</institution-id><institution>Stellenbosch University, Faculty of Medicine and Health Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Tygerberg</named-content></addr-line><country>South Africa</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00ayhx656</institution-id><institution>Department of Global Health, Brighton and Sussex Medical School, University of Sussex</institution></institution-wrap><addr-line><named-content content-type="city">Brighton</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/034m6ke32</institution-id><institution>Africa Health Research Institute</institution></institution-wrap><addr-line><named-content content-type="city">Durban, KwaZulu-Natal</named-content></addr-line><country>South Africa</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jx3x895</institution-id><institution>Collaborative Centre for Inclusion Health, University College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jx3x895</institution-id><institution>Division of Infection and Immunity, University College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Rodriguez-Barraquer</surname><given-names>Isabel</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>University of California, San Francisco</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Franco</surname><given-names>Eduardo</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>McGill University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>09</day><month>02</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e81070</elocation-id><history><date date-type="received" iso-8601-date="2022-07-01"><day>01</day><month>07</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-01-19"><day>19</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement>© 2023, Martyn et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Martyn et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81070-v1.pdf"/><abstract><p>Hepatitis B virus (HBV) infection represents a significant global health threat, accounting for 300 million chronic infections and up to 1 million deaths each year. HBV disproportionately affects people who are under-served by health systems due to social exclusion, and can further amplify inequities through its impact on physical and mental health, relationship with stigma and discrimination, and economic costs. The ‘inclusion health’ agenda focuses on excluded and vulnerable populations, who often experience barriers to accessing healthcare, and are under-represented by research, resources, interventions, advocacy, and policy. In this article, we assimilate evidence to establish HBV on the inclusion health agenda, and consider how this view can inform provision of better approaches to diagnosis, treatment, and prevention. We suggest approaches to redress the unmet need for HBV interventions among excluded populations as an imperative to progress the global goal for the elimination of viral hepatitis as a public health threat.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>hepatitis b virus</kwd><kwd>inclusion health</kwd><kwd>sustainable development goals</kwd><kwd>refugee health</kwd><kwd>health inequality</kwd><kwd>homelessness</kwd><kwd>elimination</kwd><kwd>public health</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>110110</award-id><principal-award-recipient><name><surname>Matthews</surname><given-names>Philippa C</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010438</institution-id><institution>Francis Crick Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Matthews</surname><given-names>Philippa C</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012621</institution-id><institution>University College London Hospitals Biomedical Research Centre</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Matthews</surname><given-names>Philippa C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Hepatitis B virus infection is a neglected challenge among communities who are under-served by conventional models of healthcare, requiring enhanced interventions to reduce inequity.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Hepatitis B virus (HBV) infection is estimated to account for 300 million chronic infections and 1 million deaths each year (<xref ref-type="bibr" rid="bib134">World Health Organization, 2021</xref>). The global burden of HBV infection is unevenly distributed, with particularly high prevalence in some populations in Africa and South East Asia (<xref ref-type="bibr" rid="bib21">Cooke et al., 2019</xref>). Likewise, HBV is not experienced equally across society, with a disproportionate prevalence and impact on marginalised and deprived populations, whose needs are poorly met by existing healthcare research, services, interventions and policies (<xref ref-type="bibr" rid="bib90">O’Hara et al., 2017</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). The ‘inclusion health’ agenda focuses on these populations, setting out to identify and address health and social inequities, for example barriers to accessing mainstream healthcare services (<xref ref-type="bibr" rid="bib103">Royal College of Physicians, 2022</xref>; <xref ref-type="bibr" rid="bib3">Aldridge et al., 2018</xref>). These groups include, but are not limited to, migrants in vulnerable situations, people experiencing homelessness (PEH), individuals with substance use disorders, commercial sex workers (CSW), incarcerated individuals, and Roma and Traveller communities (<xref ref-type="bibr" rid="bib103">Royal College of Physicians, 2022</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Characteristics of HBV in inclusion health populations.</title><p>(<bold>A</bold>) Illustration of the overlapping characteristics that may be present among different inclusion populations and people living with HBV infection. (<bold>B</bold>) Relationship between migrancy and asylum-seeking status as a risk factor for HBV infection. (<bold>C</bold>) Representation of complex relationship between HBV infection and PEH, where other factors include for example injecting drug use, transactional sex, mental illness (<xref ref-type="bibr" rid="bib44">Freeland et al., 2021</xref>; <xref ref-type="bibr" rid="bib65">Ly et al., 2021a</xref>). HBV – hepatitis B virus; PEH - People experiencing homelessness. Figure created in <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">BioRender.com</ext-link> with a licence to publish.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81070-fig1-v1.tif"/></fig><p>Viral hepatitis is recognised as a global health priority within the United Nations Sustainable Development Goals 2030 (SDG30). These underpin ambitious targets including 90% HBV vaccine coverage, reducing new chronic infections and new infections by 90% and attributable mortality by 65% (<xref ref-type="bibr" rid="bib21">Cooke et al., 2019</xref>). Vaccination against HBV, including universal birth dose administration, is a key elimination strategy and is estimated to have prevented 310 million cases of HBV infection between 1990 and 2020 (<xref ref-type="bibr" rid="bib21">Cooke et al., 2019</xref>, <xref ref-type="bibr" rid="bib27">de Villiers et al., 2021</xref>). However, birth dose vaccine implementation has been slow in reaching the most vulnerable populations, while a three-dose vaccine schedule remains a challenge (<xref ref-type="bibr" rid="bib27">de Villiers et al., 2021</xref>). Lack of education and awareness, inadequate living conditions, lack of access to healthcare services, and poverty and stigma among marginalised populations create a permissive environment for HBV transmission. Chronic HBV infection usually remains asymptomatic until late complications (liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC)). Silent infection, in combination with barriers to testing in the most affected populations, explains why only an estimated 10% of those living with HBV infection are diagnosed (<xref ref-type="bibr" rid="bib90">O’Hara et al., 2017</xref>).</p><p>There is no cure for HBV, but antivirals (nucleos(t)ide analogue agents) can suppress viral replication. Based on international treatment guidelines, only a minority of those with chronic infection are eligible for treatment, and a small proportion of these can actually access consistent therapy (<xref ref-type="bibr" rid="bib78">McNaughton et al., 2021</xref>). Risk stratification requires consistent surveillance (including clinical review, imaging and laboratory tests), but this can feel burdensome and irrelevant for some people living with asymptomatic infection and/or those who do not meet treatment criteria (<xref ref-type="bibr" rid="bib82">Mofokeng, 2021</xref>, <xref ref-type="bibr" rid="bib1">Adjei et al., 2019</xref>). Moreover, HBV receives only a fraction of global research funding allocated to major infectious diseases. For example, in 2022, projected US funding for HIV research is 20-fold greater than for HBV, despite the lower number of people living with HIV infection (<xref ref-type="bibr" rid="bib85">National institutes of health, 2022</xref>). Therefore, HBV remains a major public health threat, with 1.5 million new infections each year and more annual deaths than malaria or HIV (<xref ref-type="bibr" rid="bib90">O’Hara et al., 2017</xref>, <xref ref-type="bibr" rid="bib47">Graber-Stiehl, 2018</xref>).</p><p>An advocate with lived experience of HBV infection described the HBV community as ‘the forgotten people’, a description that is also pertinent to inclusion health populations (<xref ref-type="bibr" rid="bib72">Matthews et al., 2022a</xref>, <xref ref-type="bibr" rid="bib3">Aldridge et al., 2018</xref>). These exclusions may lead to an increased risk of HBV infection, are amplified by HBV infection, and lead to greater morbidity and mortality as a result of inadequate access to care. In resource-limited settings, where the burden of HBV infection is greatest, the inequities are amplified.</p><p>We have collated evidence for the impact of HBV in some of these marginalised populations globally, assimilating data and identifying knowledge gaps in order to inform the HBV agenda in inclusion health. Addressing the complex intersection of social exclusion and HBV infection is essential to support progress towards global elimination goals.</p><sec id="s1-1"><title>HBV infection in inclusion health populations</title><p>In this section, we review data for different populations who are frequently marginalised and under-served by healthcare provision. The characteristics, experiences and needs of these groups are diverse, but also have features in common, and approaches should be integrated as far as possible.</p><sec id="s1-1-1"><title>Migrants</title><p>By the end of 2020, there were 281 million international migrants, equivalent to 3.6% of the world’s population (<xref ref-type="bibr" rid="bib54">International organisation for migration, 2021</xref>). A significant proportion (approaching 90 million) are displaced due to conflict, political instability, and natural disasters. In Europe, more than half of 49 million migrants born outside of the European Economic Area came from nations where HBV endemicity is either intermediate (2–8%) or high (&gt;8%), explaining the higher prevalence of HBV infection in migrants (5%), and asylum seekers (10%) compared to the general population (1%) in Europe (<xref ref-type="bibr" rid="bib37">European Centre for Disease Prevention and Control, 2016</xref>; <xref ref-type="bibr" rid="bib57">Kim et al., 2021</xref>; <xref ref-type="table" rid="table1">Table 1</xref>). Descriptive studies from Italy and the UK provide some insight into HBV infection among migrants and unaccompanied asylum-seeking children (<xref ref-type="table" rid="table2">Table 2</xref>; <xref ref-type="bibr" rid="bib98">Prestileo et al., 2022</xref>, <xref ref-type="bibr" rid="bib19">Colucci et al., 2022</xref>; <xref ref-type="bibr" rid="bib74">Mazzitelli et al., 2021</xref>; <xref ref-type="bibr" rid="bib6">Armitage et al., 2022</xref>; <xref ref-type="bibr" rid="bib126">Williams et al., 2020a</xref>, <xref ref-type="bibr" rid="bib129">World Health Organization, 2002</xref>), reporting risks of infection that apply before, during and after relocation (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In some countries, including the UK, asylum seekers may be moved hundreds of miles away at short notice, disrupting any continuity of care (<xref ref-type="bibr" rid="bib42">Farrant et al., 2022</xref>; <xref ref-type="bibr" rid="bib132">World Health Organization, 2018b</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Top 20 origins of international migrants in 2020 (millions), HBV prevalence and progress towards SDG 30 goals for elimination of HBV as a public health threat.</title><p>Data - United Nations Department of Economic and Social Affairs, Population Division (2020b). International Migrant Stock 2020. <ext-link ext-link-type="uri" xlink:href="https://www.un.org/development/desa/pd/content/international-migrant-stock">https://www.un.org/development/desa/pd/content/international-migrant-stock</ext-link>; The Polaris Observatory, CDA Foundation; <ext-link ext-link-type="uri" xlink:href="https://cdafound.org/polaris-countries-compare/">https://cdafound.org/polaris-countries-compare/</ext-link>. HBV – Hepatitis B virus. SDG – Sustainable Development Goal.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Country of Origin</th><th align="left" valign="top">Number of International Migrants (millions)</th><th align="left" valign="top">HBV Prevalence<xref ref-type="table-fn" rid="table1fn1">*</xref></th><th align="left" valign="top">90% Diagnosed<xref ref-type="table-fn" rid="table1fn2">†</xref></th><th align="left" valign="top">80% Treated<xref ref-type="table-fn" rid="table1fn2">†</xref></th><th align="left" valign="top">65% Reduction in Mortality<xref ref-type="table-fn" rid="table1fn2">†</xref></th><th align="left" valign="top">Reduced Prevalence in 5 year olds<xref ref-type="table-fn" rid="table1fn2">†</xref></th></tr></thead><tbody><tr><td align="left" valign="top">India</td><td align="char" char="." valign="top">17.9</td><td style="author-callout-style-b3">3%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b3">2032</td></tr><tr><td align="left" valign="top">Mexico</td><td align="char" char="." valign="top">11.2</td><td style="author-callout-style-b2">0%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b2">2015</td></tr><tr><td align="left" valign="top">Russia</td><td align="char" char="." valign="top">10.8</td><td style="author-callout-style-b2">1%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b2">2015</td></tr><tr><td align="left" valign="top">China</td><td align="char" char="." valign="top">10.5</td><td style="author-callout-style-b3">6%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b2">2021</td></tr><tr><td align="left" valign="top">Syria</td><td align="char" char="." valign="top">8.5</td><td style="author-callout-style-b3">6%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td></tr><tr><td align="left" valign="top">Bangladesh</td><td align="char" char="." valign="top">7.4</td><td style="author-callout-style-b3">5%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b3">2043</td></tr><tr><td align="left" valign="top">Pakistan</td><td align="char" char="." valign="top">6.3</td><td style="author-callout-style-b2">1%</td><td style="author-callout-style-b3">2042</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b3">2036</td></tr><tr><td align="left" valign="top">Ukraine</td><td align="char" char="." valign="top">6.1</td><td style="author-callout-style-b2">1%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b2">2030</td></tr><tr><td align="left" valign="top">Philippines</td><td align="char" char="." valign="top">6.1</td><td style="author-callout-style-b6">10%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td></tr><tr><td align="left" valign="top">Afghanistan</td><td align="char" char="." valign="top">5.9</td><td style="author-callout-style-b3">3%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b3">2045</td></tr><tr><td align="left" valign="top">Venezuela</td><td align="char" char="." valign="top">5.4</td><td style="author-callout-style-b2">1%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b3">2031</td></tr><tr><td align="left" valign="top">Poland</td><td align="char" char="." valign="top">4.8</td><td style="author-callout-style-b2">1%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b2">2015</td></tr><tr><td align="left" valign="top">United Kingdom</td><td align="char" char="." valign="top">4.7</td><td style="author-callout-style-b2">1%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b2">2020</td></tr><tr><td align="left" valign="top">Indonesia</td><td align="char" char="." valign="top">4.6</td><td style="author-callout-style-b3">7%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td></tr><tr><td align="left" valign="top">Kazakhstan</td><td align="char" char="." valign="top">4.2</td><td style="author-callout-style-b3">4%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b2">2027</td></tr><tr><td align="left" valign="top">Palestine</td><td align="char" char="." valign="top">4.0</td><td style="author-callout-style-b3">2%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b2">2015</td></tr><tr><td align="left" valign="top">Romania</td><td align="char" char="." valign="top">4.0</td><td style="author-callout-style-b3">3%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b2">2025</td></tr><tr><td align="left" valign="top">Germany</td><td align="char" char="." valign="top">3.9</td><td style="author-callout-style-b2">0%</td><td style="author-callout-style-b3">2039</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b2">2015</td></tr><tr><td align="left" valign="top">Myanmar</td><td align="char" char="." valign="top">3.7</td><td style="author-callout-style-b6">8%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td></tr><tr><td align="left" valign="top">Egypt</td><td align="char" char="." valign="top">3.6</td><td style="author-callout-style-b2">1%</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b6">2051</td><td style="author-callout-style-b2">2018</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><label>*</label><p>Green -Low HBV prevalence (&lt;2%); Amber - intermediate HBV prevalence (2–8%); Red - high HBV (prevalence &gt;8%).</p></fn><fn id="table1fn2"><label>†</label><p>Green - HBV SDG reached before 2030; Amber - SDG reached 2031–50; Red - SDG reached &gt;2050.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Key review and study observations pertinent to HBV infection among inclusion health populations.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Inclusion health population</th><th align="left" valign="bottom">Citation</th><th align="left" valign="bottom">Study type</th><th align="left" valign="bottom">Country</th><th align="left" valign="bottom">Key observations</th></tr></thead><tbody><tr><td align="left" valign="bottom">PEH, PWID, Incarcerated individuals, sex workers</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib3">Aldridge et al., 2018</xref></td><td align="left" valign="bottom">Systematic Review and Meta-analysis</td><td align="left" valign="bottom">High-income countries</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>All-cause mortality significantly increased for inclusion health populations studied:</p><list list-type="bullet"><list-item><p>Female SMR 11.86 (95% CI 10.42–13.3; I<sup>2</sup> 91.5%)</p></list-item><list-item><p>Male SMR 7.88 (95% CI 6.40–9.37; I<sup>2</sup> 98.1%)</p></list-item></list></list-item><list-item><p>High SMR for infectious diseases:</p><list list-type="bullet"><list-item><p>11.43 (95% CI 6.91–15.94; I<sup>2</sup> 97%)</p></list-item><list-item><p>High prevalence of hepatitis B</p></list-item></list></list-item><list-item><p>Sex workers contributed only 4.2% datapoints, compared to people with substance use disorders contributing 42.1%</p></list-item></list></td></tr><tr><td align="left" valign="bottom">PWID, PEH, Previous incarceration</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib115">Taylor et al., 2019</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">UK</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>346 participants</p></list-item><list-item><p>Level of self-declared HBV vaccination 52.3%</p></list-item><list-item><p>Being female associated with lower HBV vaccine uptake (OR 2.37, 95% CI 1.23–4.57, p=0.01)</p></list-item><list-item><p>Intravenous drug use protective against incomplete vaccination (OR 0.23, 95% CI 0.08–0.62, p=0.004)</p></list-item><list-item><p>2 or more risk factors associated with protection against incomplete vaccination (OR 0.19, 95% CI 0.09–0.39, p&lt;0.001)</p></list-item></list></td></tr><tr><td align="left" valign="bottom">Migrants</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib98">Prestileo et al., 2022</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Italy</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Screening migrants for HBV and other blood borne viruses on arrival to Italy is acceptable to target population (&gt;95% uptake)</p></list-item><list-item><p>Risk of HBV infection was associated with:</p><list list-type="bullet"><list-item><p>Female sex (aOR 2.47,95% CI 1.90–3.20, p=0.003)</p></list-item><list-item><p>Physical and/or sexual violence on migration journey (aOR 2.24,95% CI 1.87–3.55,p&lt;0.001)</p></list-item></list></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib19">Colucci et al., 2022</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Italy</td><td align="left" valign="bottom">Increased risk of BBV acquisition persisted after arrival in Italy, possibly due to living conditions, sex work, lack of access to healthcare and social support</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib74">Mazzitelli et al., 2021</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Italy</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Migrants appeared to have severe chronic HBV disease requiring intervention:</p><list list-type="bullet"><list-item><p>&gt;2/3 of migrants with CHB had moderate/ severe liver disease and were eligible for HBV treatment</p></list-item><list-item><p>&gt;10% diagnosed with HBV had liver cirrhosis</p></list-item></list></list-item><list-item><p>&lt;50% of migrants diagnosed with CHB were retained in care at 1 year</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib6">Armitage et al., 2022</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">UK</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>UASC in London (n=101)</p></list-item><list-item><p>16% female, median age 16 (range 14–17)</p></list-item><list-item><p>Physical assault/abuse reported in 67%</p></list-item><list-item><p>13% disclosed sexual assault/abuse (38% of females)</p></list-item><list-item><p>Mental health symptoms in 77%</p></list-item><list-item><p>6% prevalence HBV infection</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib126">Williams et al., 2020a</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">UK</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>UASC in London (n=252)</p></list-item><list-item><p>19 countries (majority from Afghanistan, Eritrea, Albania)</p></list-item><list-item><p>4.8% prevalence HBV infection (highest prevalence from Sudan and Afghanistan)</p></list-item><list-item><p>Many co-infections (TB, Schistosomiasis most common)</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib33">Eborall et al., 2020</xref></td><td align="left" valign="bottom">Qualitative</td><td align="left" valign="bottom">UK</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Very low knowledge and low personal perceived risk of acquiring HBV among migrants</p></list-item><list-item><p>Majority of migrants with positive views around screening for infectious diseases including HBV. Reservations included:</p><list list-type="bullet"><list-item><p>Concerns over results impacting immigration and/or asylum applications</p></list-item><list-item><p>Concerns over delay receiving the results</p></list-item><list-item><p>Language barriers</p></list-item><list-item><p>Stigma</p></list-item></list></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib114">Tasa et al., 2021</xref></td><td align="left" valign="bottom">Retrospective cohort</td><td align="left" valign="bottom">Finland</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>62 pregnancies, undocumented women</p></list-item><list-item><p>4 women received no antenatal care, 3 denied antenatal care</p></list-item><list-item><p>71% received less that the recommended number of antenatal vistits</p></list-item><list-item><p>3% HBV seroprevalence, significantly higher than all pregnant women (p=0.007)</p></list-item><list-item><p>2/3rds attended first prenatal visit in 2<sup>nd</sup> or 3<sup>rd</sup> trimester</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib8">Bierhoff et al., 2021</xref></td><td align="left" valign="bottom">Mixed-methods</td><td align="left" valign="bottom">Thailand</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Migrant pregnant women, northern Thailand</p></list-item><list-item><p>757 knowledge and attitude studies:</p><list list-type="bullet"><list-item><p>Low knowledge about HBV transmission, infection or vaccination (28% correct response)</p></list-item></list></list-item><list-item><p>Qualitative analysis found counselling should:</p></list-item><list-item><p>Use appropriate language, tailored to local health literacy level, provide pertinent information, be repeated over antenatal period, ensure privacy</p></list-item></list></td></tr><tr><td align="left" valign="bottom" rowspan="2">PEH</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib65">Ly et al., 2021a</xref></td><td align="left" valign="bottom">Narrative review</td><td align="left" valign="bottom">Global</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>HBV seroprevalence higher than in non-PEH</p></list-item><list-item><p>Studies have associated HBV past infection in PEH with: older age, MSM, insertive anal sex, Injecting drug use, alcohol use</p></list-item></list></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib4">Al Shakarchi et al., 2020</xref></td><td align="left" valign="bottom">Systematic review and meta-analysis</td><td align="left" valign="bottom">Global</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Compared to non-homeless individuals, homeless individuals:</p></list-item><list-item><p>More likely to have cardiovascular disease (pooler OR 2.96, 95% CI 2.80–3.13 l p&lt;0.001, I=99.1%)</p></list-item><list-item><p>More likely to have hypertension (pooled OR 1.38–1.75, p=0.007)</p></list-item><list-item><p>Higher cardiovascular mortality (age-standardised SMR range 2.6–6.4)</p></list-item></list></td></tr><tr><td align="left" valign="bottom">PWID</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib28">Degenhardt et al., 2017</xref></td><td align="left" valign="bottom">Multistage systematic review</td><td align="left" valign="bottom">Global</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Estimated global seroprevalence active HBV of 9% (95% UI 5.1–13.2%)</p></list-item><list-item><p>Highest seroprevalence in:</p><list list-type="bullet"><list-item><p>East and SE Asia (20%)</p></list-item><list-item><p>Azerbaijan, Egypt, Cote d’Ivoire, Lithuania, Belarus, Czech Republic (&gt;10%)</p></list-item></list></list-item><list-item><p>21.7% (15.8–27.9) recently (within past year) experienced homelessness/ unstable housing</p></list-item><list-item><p>57.9% (50.5–65.2) with history of incarceration</p></list-item></list></td></tr><tr><td align="left" valign="bottom">People who misuse alcohol</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib68">Magri et al., 2020</xref></td><td align="left" valign="bottom">Systematic review and meta-analysis</td><td align="left" valign="bottom">Global</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>12,204 alcohol users, mostly men</p></list-item><list-item><p>Estimated global seroprevalence of active HBV infection was 20% (95% CI 19–20)</p></list-item><list-item><p>Substantial heterogeneity between studies (I<sup>2</sup>=96.7%)</p></list-item></list></td></tr><tr><td align="left" valign="bottom">Incarcerated people</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib29">Dolan et al., 2016</xref></td><td align="left" valign="bottom">Systematic review and meta-analysis</td><td align="left" valign="bottom">Global</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Global chronic HBV seroprevalence among incarcerated individuals estimated at 4.8%</p></list-item><list-item><p>Regions with the highest HBsAg seroprevalence were:</p></list-item><list-item><p>West and central Africa (23.5%, 95% CI 19.8–27.5)</p></list-item><list-item><p>Eastern Europe and central Asia (10.4%; 95% CI 1.9–24.6%)</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib84">Nakitanda et al., 2021</xref></td><td align="left" valign="bottom">Descriptive analysis</td><td align="left" valign="bottom">Europe</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Data from WHO Prison’s European Database and ECDC hepatitis prevalence database</p></list-item><list-item><p>HBsAg seroprevalence ranged from 0% in maximum-security prison in the UK to 25% in two Bulgarian juvenile detention centres</p></list-item><list-item><p>Universal HBV screening on opt-out basis available in 31% of reporting countries</p></list-item><list-item><p>Condoms and lubricants offered free of charge in 46% and 15% of reporting countries, respectively</p></list-item><list-item><p>Universal HBV vaccination available in 85% of reporting countries</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib56">Kamarulzaman et al., 2016</xref></td><td align="left" valign="bottom">Narrative review</td><td align="left" valign="bottom">Global</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>25% PWID initiate drug use in prison</p></list-item><list-item><p>Risk factors for HBV: sharing needles, sharing toothbrushes, unsterile tattooing and body piercing</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib25">Dana et al., 2013</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Iran</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Prevalence of HBV among incarcerated PWID associated with:</p><list list-type="bullet"><list-item><p>Multiple incarceration (OR 1.43, 95% CI 1.01–2.02)</p></list-item><list-item><p>Total duration of incarceration (OR 2.70 95% CI 1.94–3.74)</p></list-item></list></list-item></list></td></tr><tr><td align="left" valign="bottom">Sex workers</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib106">Schuelter-Trevisol et al., 2013</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Brazil</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>3 cities, southern Brazil</p></list-item><list-item><p>147 SWs (Male 4.5%, female 91.2%, transgender 4.3%)</p></list-item><list-item><p>3.4% HBsAg positive</p></list-item><list-item><p>Baseline prevalence &lt;2% in Brazil</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib80">Miranda et al., 2021</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Brazil</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>4 cities, northern Brazil</p></list-item><list-item><p>365 FSWs</p></list-item><list-item><p>3.0% HBsAg positive</p></list-item><list-item><p>Use of illicit drugs most strongly associated with exposure to HBV (OR 44.1, 95% CI 12.7–68.6)</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib71">Matos et al., 2017</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Brazil</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>One city, mid-western Brazil</p></list-item><list-item><p>402 FSWs</p></list-item><list-item><p>1.6% HBsAg positive</p></list-item><list-item><p>Only 28% serological evidence of HBV vaccination</p></list-item><list-item><p>Exposure to HBV associated with:</p><list list-type="bullet"><list-item><p>Age &gt;40 (OR 3.5, 95% CI 1.5–7.9, p&lt;0.001)</p></list-item><list-item><p>Being in education <underline>&lt;</underline>4 yrs (OR 3.2, 95% CI 1.4–7.4, p&lt;0.009)</p></list-item><list-item><p>Being single (OR 2.0, 95% CI 1.1–3.8, p&lt;0.028)</p></list-item><list-item><p>Meeting clients on the street (OR 2.5, 95% CI 1.4–4.4, p&lt;0.003)</p></list-item></list></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib62">Leuridan et al., 2005</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Belgium</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>129 MSWs</p></list-item><list-item><p>3.3% HBsAg positive</p></list-item><list-item><p>Only 9.1% anti-HBs (i.e. evidence of HBV vaccination)</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib69">Mak et al., 2003</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Belgium</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>1096 SWs (97.8% female)</p></list-item><list-item><p>0.6% HBsAg positive</p></list-item><list-item><p>Only 7% anti-HBs (i.g. evidence of previous HBV vaccination)</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Dos Ramos Farías et al., 2011</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Argentina</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>273 trans female sex workers (TSW), 114 MSW</p></list-item><list-item><p>HBV exposure 40% TSW, 22% MSW</p></list-item><list-item><p>Total HbSAg prevalence 1.6%</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib116">Todd et al., 2010</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Afghanistan</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>HBV infection associated with:</p><list list-type="bullet"><list-item><p>&gt;= 12 clients monthly (OR 3.30, 95% CI 1.46–7.47)</p></list-item><list-item><p>Ever using drugs (OR 1.77, 95% CI1.55–2.02) or alcohol (OR 2.96, 95% CI 2.15–4.07)</p></list-item><list-item><p>Having children (OR 1.52, 95% CI 1.41–1.64)</p></list-item></list></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib55">Jeal and Salisbury, 2004</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">UK</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>24% vaccinated against HBV</p></list-item><list-item><p>Only 30% booked in first trimester and attended all antenatal appointments</p></list-item><list-item><p>13% received no antenatal care until admitted</p></list-item><list-item><p>Barriers: waiting times, fear of judgement</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib10">Bitty-Anderson et al., 2021</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Togo</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>1036 female sex workers</p></list-item><list-item><p>HbsAg prevalence 9.9%</p></list-item><list-item><p>HBV infection associated with:</p><list list-type="bullet"><list-item><p>Recruitment out of the capital city (aOR 6.63; 95% CI 2.51–13.4-, <italic>P</italic>&lt;0.001)</p></list-item><list-item><p>Never using condoms for vaginal intervourse (OR 3.14; 95% CI 1.02–8.71)</p></list-item></list></list-item></list></td></tr><tr><td align="left" valign="bottom">Roma and Traveller populations</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib67">Macejova et al., 2020</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Slovakia</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>452 Roma people screened</p></list-item><list-item><p>Increased HBsAg positivity compared to age-matched general population (RR 4.47, 95% CI 2.36–8.42; <italic>P</italic>&lt;0.001)</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib48">Gregory et al., 2014</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">UK</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>1345 Slovak-Roma patients seen in dedicated primary care clinic</p></list-item><list-item><p>9.4% HBsAg positivity (compared to 1% general UK population)</p></list-item><list-item><p>Median number of people in each household 7 (range 1–21 people)</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib122">Veselíny et al., 2014</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Slovakia</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>452 Roma people screened, risk factors assessed by questionnaire/interview</p></list-item><list-item><p>Participants who were HBsAg positive had a higher median age compared to those with no evidence of HBV exposure (35.2, vs 30.7, <italic>P</italic>=0.028)</p></list-item><list-item><p>A higher proportion of male participants were HBsAg positive, compared to those with no evidence of HBV exposure (51% vs 31%, <italic>P</italic>=0.005)</p></list-item><list-item><p>A higher proportion of incarcerated people, and people with tattoos, had HBV exposure (HBc IgG positive) compared to those with no history of exposure (HBc IgG negative) (14% vs 6%, p 0.016 and 44% vs 32%, p 0.035, respectively)</p></list-item></list></td></tr><tr><td align="left" valign="bottom">Indigenous Populations</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib26">Davies et al., 2019</xref></td><td align="left" valign="bottom">Cross-sectional</td><td align="left" valign="bottom">Australia</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>35,633 individuals tested in Northern Territory between 2007–2011</p></list-item><list-item><p>HBsAg positivity was 3·40% (95%CI 3·19–3·61), being higher in Indigenous (6·08% [5·65%–6·53%]) than non-Indigenous (1·56% [1·38%–1·76%]) Australians, <italic>P</italic>&lt;0·0001</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib99">Qama et al., 2021</xref></td><td align="left" valign="bottom">Retrospective cohort</td><td align="left" valign="bottom">Australia</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>100 790 individuals were tested (33.4% Indigenous) between 1991 and 2011 (26.1% of the 2011 NT population)</p></list-item><list-item><p>In 2011, the proportion of HBV positive individuals in the NT was 3.17% (5.22% in Indigenous populations) compared to previous 2011 estimates of 1.70% (3.70% in Indigenous populations)</p></list-item><list-item><p>Evidence of suboptimal vaccine efficacy by breakthrough anti-HBc positivity in vaccinated individuals was demonstrated in 3.1% of the vaccinated cohort, of which 86.4% identified as Indigenous (HR 1.17)</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib34">Einsiedel et al., 2013</xref></td><td align="left" valign="bottom">Retrospective cohort</td><td align="left" valign="bottom">Australia</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>558 indigenous and 55 non-indigenous community residence of central Australia</p></list-item><list-item><p>HBsAg more common in indigenous compared to non-indigenous (12.9% vs 6.7%)</p></list-item><list-item><p>Other infections and non-communicable diseases more common in indigenous than non-indigenous population</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib92">Osiowy et al., 2013</xref></td><td align="left" valign="bottom">Narrative review</td><td align="left" valign="bottom">USA, Canada, Greenland</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>High prevalence of HBV among indigenous populations (e.g. Inuit of Greenland 3–29% HBsAg positivity, Alsaka Native and Canadian Far North 3–20% depending on community investigated), before introduction of HBV vaccine</p></list-item><list-item><p>Variety of genotype observed which may alter natural history of disease</p></list-item><list-item><p>Genotype B6 (now known as B5) unique to this region, reported to have a more benign disease course</p></list-item></list></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib104">Russell et al., 2019</xref></td><td align="left" valign="bottom">Systematic review</td><td align="left" valign="bottom">Latin America</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Reviewed 62 studies from 12 countries</p></list-item><list-item><p>High endemicity (&gt;8%) of hepatitis B was found in some indigenous peoples in Mexico (Huichol) (9.4%), Venezuela (Yanomami: 14.3%; Japreira: 29.5%) and among Afro-descendant quilombola populations in Brazil (Frechal: 12.5%; Furnas do Dionísio: 8.4% in 2008, 9.2% in 2003)</p></list-item></list></td></tr></tbody></table><table-wrap-foot><fn><p>SMR Standardised Mortality Ratio; aOR adjusted odds ratio; OR odds ratio; RR relative risk; CI confidence interval; HBV hepatitis B virus; UI Uncertainty Interval; MSM men who have sex with men; PEH people experiencing homelessness, PWID people who inject drugs; UASC unaccompanied asylum-seeking children; HBsAg Hepatitis B surface antigen (active HBV infection); HBc Hepatitis B core antibody</p></fn></table-wrap-foot></table-wrap></sec><sec id="s1-1-2"><title>People experiencing homelessness</title><p>Approximately 150 million people worldwide were considered homeless in 2020 (<xref ref-type="bibr" rid="bib15">Chamie, 2017</xref>). People experiencing homelessness (PEH) endure extreme social exclusion and have substantially increased mortality from any cause compared to a socially deprived population (<xref ref-type="table" rid="table2">Table 2</xref>; <xref ref-type="bibr" rid="bib3">Aldridge et al., 2018</xref>). Seroprevalence surveys, although of varying size and quality, report higher HBV seroprevalence among PEH compared to the housed population (<xref ref-type="bibr" rid="bib65">Ly et al., 2021a</xref>). Homelessness may be a risk factor for HBV infection or vice versa, while there are also shared risk factors which include associations with place of birth, older age, sexual partners with a history of hepatitis, and injecting drug or alcohol use (<xref ref-type="bibr" rid="bib65">Ly et al., 2021a</xref>, <xref ref-type="bibr" rid="bib66">Ly et al., 2021b</xref>; <xref ref-type="fig" rid="fig1">Figure 1C</xref>). Low HBV vaccination uptake among PEH may relate to either never being offered the vaccine, or being unable to access follow-up doses (<xref ref-type="bibr" rid="bib66">Ly et al., 2021b</xref>, <xref ref-type="bibr" rid="bib115">Taylor et al., 2019</xref>).</p><p>Among PEH, fear of judgement and stigma relating to homelessness can lead to distrust of healthcare workers and services, basic needs (food, clothing and shelter) are prioritised over long-term healthcare needs, and additional barriers are common (lack of insurance, transport costs, and long waiting times in unfamiliar environments) (<xref ref-type="bibr" rid="bib24">Crone et al., 2022</xref>; <xref ref-type="bibr" rid="bib7">Becker and Foli, 2022</xref>; <xref ref-type="bibr" rid="bib93">Paisi et al., 2022</xref>). High prevalence of co-morbid conditions compounds social exclusion, for example severe mental illness or substance use disorders (<xref ref-type="bibr" rid="bib108">Shepherd-Banigan, 2021</xref>).</p></sec><sec id="s1-1-3"><title>People who misuse drugs and alcohol</title><p>It is estimated that there are 15.6 million People Who Inject Drugs (PWID) between the ages of 15–64 years worldwide (<xref ref-type="bibr" rid="bib28">Degenhardt et al., 2017</xref>), while an estimated 283 million people have alcohol use disorders (<xref ref-type="bibr" rid="bib131">World Health Organization, 2018a</xref>). HBV infection disproportionately affects people who misuse drugs and alcohol (<xref ref-type="table" rid="table2">Table 2</xref>; <xref ref-type="bibr" rid="bib28">Degenhardt et al., 2017</xref>; <xref ref-type="bibr" rid="bib68">Magri et al., 2020</xref>). Alcohol use is associated with increased high-risk sexual activity, drug use, and sharing injecting equipment, and therefore may increase risk of HBV transmission (<xref ref-type="bibr" rid="bib5">Arasteh et al., 2008</xref>), while alcohol acts synergistically with HBV infection to accelerate liver damage (<xref ref-type="bibr" rid="bib46">Gitto et al., 2009</xref>; <xref ref-type="bibr" rid="bib63">Li et al., 2019</xref>).</p><p>Perceived lack of need, competing priorities (e.g. avoiding opioid withdrawal), discrimination, stigma and difficulty in navigating health systems are reasons that PWID and people with alcohol use disorder may avoid seeking care (<xref ref-type="bibr" rid="bib83">Motavalli et al., 2021</xref>; <xref ref-type="bibr" rid="bib139">Zewdu et al., 2019</xref>; <xref ref-type="bibr" rid="bib22">Costa et al., 2020</xref>). Inadequate funding for harm reduction and addiction programmes is a barrier to HBV prevention. Criminalisation and imprisonment of PWID exacerbates transmission and creates further barriers to consistent HBV care provision (<xref ref-type="bibr" rid="bib91">O’Keefe et al., 2017</xref>). Finally, a fifth of PWID have experienced recent homelessness (within 1 year) and over two-thirds have a history of incarceration (<xref ref-type="bibr" rid="bib28">Degenhardt et al., 2017</xref>; <xref ref-type="bibr" rid="bib100">Rashti et al., 2020</xref>). This intersection of overlapping risks further amplifies HBV infection and increases the challenges for healthcare.</p></sec><sec id="s1-1-4"><title>Incarcerated people</title><p>At the end of 2021, the worldwide prison population was at least 10.77 million (<xref ref-type="bibr" rid="bib41">Fair and Walmsley, 2021</xref>). The majority of published HBV literature representing prisons consists of small cross sectional seroprevalence studies, which do not reflect the dynamic nature of prison populations (<xref ref-type="bibr" rid="bib128">Wirtz et al., 2018</xref>; <xref ref-type="bibr" rid="bib29">Dolan et al., 2016</xref>). Nevertheless, HBV is over-represented in incarcerated individuals, with an estimated global HBsAg prevalence of 4.8% (<xref ref-type="bibr" rid="bib29">Dolan et al., 2016</xref>; <xref ref-type="bibr" rid="bib84">Nakitanda et al., 2021</xref>).</p><p>Prisons create a complex intersection of individual, social and environmental challenges, and have been described as a ‘concentration mechanism’ leading to amplification and dissemination of infectious diseases (<xref ref-type="bibr" rid="bib56">Kamarulzaman et al., 2016</xref>), particularly when injecting drug use and sex work are criminalised. 25% of PWID report initiating drug use in prisons and incarceration is associated with a doubled risk of re-initiating injecting drug use (<xref ref-type="bibr" rid="bib45">Genberg et al., 2015</xref>; <xref ref-type="bibr" rid="bib56">Kamarulzaman et al., 2016</xref>). Sharing contaminated needles for injecting drugs, sharing tooth brushes, unsterile tattooing, body piercing and high-risk sexual activity also represent potential routes of HBV transmission within prisons (<xref ref-type="bibr" rid="bib56">Kamarulzaman et al., 2016</xref>; <xref ref-type="bibr" rid="bib81">Moazen et al., 2018</xref>; <xref ref-type="bibr" rid="bib58">Kowo et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Harawa et al., 2010</xref>). This risk continues beyond prison; the immediate period following release is associated with high risk of heightened sexual behaviours, and drug/alcohol use (<xref ref-type="bibr" rid="bib56">Kamarulzaman et al., 2016</xref>; <xref ref-type="bibr" rid="bib29">Dolan et al., 2016</xref>; <xref ref-type="bibr" rid="bib9">Binswanger et al., 2007</xref>). Frequency and duration of incarceration are also positively associated with prevalence of HBV infection (<xref ref-type="bibr" rid="bib25">Dana et al., 2013</xref>). Given the overlap of this population and many other HBV risk factors, this is a particularly important target group in which HBV interventions need to be carefully focused, both during and after incarceration periods.</p></sec><sec id="s1-1-5"><title>People who engage in transactional sex</title><p>This group is highly heterogenous, representing commercial sex workers (CSW) but also a wider group of individuals practising intermittent transactional sex (in exchange for goods, drugs, accommodation etc), overlapping with PWID and PEH populations (<xref ref-type="table" rid="table2">Table 2</xref>). Sex workers are underrepresented in the literature and robust data are lacking (<xref ref-type="bibr" rid="bib3">Aldridge et al., 2018</xref>). HBV prevalence varies between countries and sex worker populations; cross-sectional data from Brazil suggest regional differences in HBV seroprevalence (<xref ref-type="bibr" rid="bib106">Schuelter-Trevisol et al., 2013</xref>; <xref ref-type="bibr" rid="bib80">Miranda et al., 2021</xref>; <xref ref-type="bibr" rid="bib71">Matos et al., 2017</xref>), and higher risk groups include male sex workers and trans-female sex workers (<xref ref-type="bibr" rid="bib62">Leuridan et al., 2005</xref>; <xref ref-type="bibr" rid="bib31">Dos Ramos Farías et al., 2011</xref>; <xref ref-type="bibr" rid="bib69">Mak et al., 2003</xref>). Older age, marital status, having children, fewer years in education, drug and alcohol use, meeting clients on the street and high numbers of clients are associated with HBV exposure among CSWs (<xref ref-type="bibr" rid="bib80">Miranda et al., 2021</xref>; <xref ref-type="bibr" rid="bib71">Matos et al., 2017</xref>; <xref ref-type="bibr" rid="bib116">Todd et al., 2010</xref>).</p><p>A study of street-based female sex workers (FSW) in the UK found that most did not disclose their work to a primary care practitioner, and in pregnancy, 13% sought antenatal services for the first time whilst in labour, reducing opportunities to prevent mother to child transmission of HBV. Barriers to care for FSW include waiting times, fear of judgement and travelling long distances for healthcare (<xref ref-type="bibr" rid="bib55">Jeal and Salisbury, 2004</xref>; <xref ref-type="bibr" rid="bib75">Mc Grath-Lone et al., 2014</xref>).</p></sec><sec id="s1-1-6"><title>Roma and Traveller communities</title><p>These communities encompass diverse distinct cultural and ethnic groups, also including travelling show people and boat dwellers. In Europe, these populations number 10–12 million, but this is likely to be an underestimate due to high mobility and poor data capture (<xref ref-type="bibr" rid="bib23">Council of Europe, 2020</xref>). These communities experiences extreme health disparities, with a 10-year lower life expectancy than the settled population in the UK (<xref ref-type="bibr" rid="bib36">Equality and Human Rights Commission, 2017</xref>). HBV is not well studied among these populations, but in the UK a study of Roma people found a HBV surface antigen (HBsAg) prevalence of 9.4% and in Eastern Slovakia, Roma community members were four times more likely to be HBsAg-positive compared to the age-matched general population (<xref ref-type="bibr" rid="bib67">Macejova et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Gregory et al., 2014</xref>). Risk factors associated with HBV infection included being male, older age, tattoos, and previous imprisonment (<xref ref-type="bibr" rid="bib122">Veselíny et al., 2014</xref>).</p><p>Mainstream healthcare services are not inclusive towards the lifestyle and culture of travelling communities, with barriers arising through discrimination, alongside lack of fixed address and low levels of literacy (<xref ref-type="bibr" rid="bib76">McFadden et al., 2018</xref>). Belief in God’s will, prioritising work and family commitments over personal health, mistrust in healthcare services and everyday stigma likely contribute to underdiagnosis, undertreatment and lack of preventative measures for HBV infection (<xref ref-type="bibr" rid="bib98">Prestileo et al., 2022</xref>).</p></sec><sec id="s1-1-7"><title>Indigenous communities</title><p>Indigenous populations, a global term referring to people with historical ties to a land prior to colonisation, are disproportionately affected by HBV (<xref ref-type="bibr" rid="bib92">Osiowy et al., 2013</xref>; <xref ref-type="bibr" rid="bib104">Russell et al., 2019</xref>; <xref ref-type="bibr" rid="bib52">Howell et al., 2019</xref>). For example, Aboriginal Australians have a higher HBV prevalence, higher rate of liver disease, and poorer outcomes, compared to non-Indigenous Australians (<xref ref-type="bibr" rid="bib96">Plackett, 2022</xref>; <xref ref-type="bibr" rid="bib99">Qama et al., 2021</xref>; <xref ref-type="bibr" rid="bib125">Wigg et al., 2021</xref>). A variety of factors may account for this disparity, including reduced healthcare access due to remote location, social inequalities and multi-morbidity (<xref ref-type="bibr" rid="bib96">Plackett, 2022</xref>; <xref ref-type="bibr" rid="bib34">Einsiedel et al., 2013</xref>). HBV genotype may also be an important consideration; genotype C4 in Aboriginal Australians is associated with aggressive disease progression, however this impact is yet to be unpicked from the effects of social determinants of health (<xref ref-type="bibr" rid="bib26">Davies et al., 2019</xref>; <xref ref-type="bibr" rid="bib96">Plackett, 2022</xref>). In addition, there is some evidence that current HBV vaccine, which is designed against genotype A, may have reduced efficacy against C4 (<xref ref-type="bibr" rid="bib99">Qama et al., 2021</xref>). Although culturally and geographically distinct, indigenous populations across the globe face an increased burden and worse outcomes from HBV, and are poorly represented by existing data. Enhanced research, allocation of resources, services, educations and intervention is required to reduce inequities.</p></sec></sec><sec id="s1-2"><title>Sex and gender as risk factors for HBV infection</title><p>Within inclusion health populations, evidence suggests that females with HBV fare worse than males (<xref ref-type="table" rid="table2">Table 2</xref>). For example, HBV infection was twice as likely in female migrants in Italy, and a higher proportion of female migrants and unaccompanied asylum-seeking children report a history of sexual assault/abuse which represents a significant HBV transmission risk (<xref ref-type="bibr" rid="bib98">Prestileo et al., 2022</xref>, <xref ref-type="bibr" rid="bib6">Armitage et al., 2022</xref>). Being female was associated with lower HBV vaccination uptake in PEH, PWID and people with a history of incarceration in the UK (<xref ref-type="bibr" rid="bib115">Taylor et al., 2019</xref>).</p><p>It could be argued that HBV presents a ‘double jeopardy’ in females, given the risk of both individual disease and mother-to-child transmission. A Finnish study found that HBV prevalence in pregnancy was significantly higher in undocumented migrants than in the general population. Most pregnant migrants entered antenatal care late, and either received inadequate care or none at all (<xref ref-type="bibr" rid="bib114">Tasa et al., 2021</xref>). Education and awareness are also lacking among women in some inclusion health populations: pregnant migrant women in Thailand had very low levels of HBV knowledge (<xref ref-type="bibr" rid="bib8">Bierhoff et al., 2021</xref>), and despite a high prevalence of HBV (8%), more than 90% of FSW in Mumbai had not heard of HBV infection (<xref ref-type="bibr" rid="bib120">United Way Mumbai, 2017</xref>).</p><p>This female disadvantage observed in inclusion health populations with HBV is reflected in the dramatically increased all-cause mortality in females compared to males across the wider inclusion health population, with female standardised mortality ratio (SMR) 11.86 (95% CI 10.42–13.3; I<sup>2</sup> 91.5%) vs. Male SMR 7.88 (95% CI 6.40–9.37; I<sup>2</sup> 98.1%) (<xref ref-type="bibr" rid="bib3">Aldridge et al., 2018</xref>).</p><p>These observations within inclusion health populations contrast with observations from the wider population, which suggest males have worse HBV outcomes than females, with higher rates of exposure, chronicity and complications (<xref ref-type="bibr" rid="bib11">Brown et al., 2022</xref>). Further work is needed to determine whether this sexual dimorphism is truly reversed in HBV within inclusion health populations, and highlights the importance of considering HBV within the sociodemographic context of inclusion health populations as this may affect risk stratification and targeted elimination strategies.</p></sec><sec id="s1-3"><title>HBV and the Inclusion Health Agenda: A global perspective</title><p>The majority of existing research on inclusion health and HBV is biased towards high-income settings such as Europe and North America (<xref ref-type="table" rid="table2">Table 2</xref>). Gathering relevant data in some high endemicity countries, including countries in the WHO African, South-East Asian and Western Pacific regions is made more difficult due to criminalisation and/or stigmatisation of inclusion health populations for example CSW, PWID and LGBTQ+ communities. Depending on the sampling methods, available data suggest intermediate to high HBV prevalence in CSWs, PWID, and incarcerated people in African populations (<xref ref-type="bibr" rid="bib10">Bitty-Anderson et al., 2021</xref>; <xref ref-type="bibr" rid="bib28">Degenhardt et al., 2017</xref>; <xref ref-type="bibr" rid="bib29">Dolan et al., 2016</xref>; <xref ref-type="bibr" rid="bib105">Scheibe et al., 2020</xref>). Fear of discrimination by healthcare workers, possible legal consequences and refusal of services are just some of the barriers deterring inclusion health populations from seeking care and remaining in longer term follow up (<xref ref-type="bibr" rid="bib32">Duby et al., 2018</xref>). Increased difficulties collecting relevant data, heightened exclusion from healthcare services and increased HBV prevalence, mean it is of even greater importance to prioritise HBV in the inclusion health agenda globally, particularly in Africa where HBV research, advocacy, representation and investment have been neglected.</p></sec><sec id="s1-4"><title>Enhancing HBV within the Inclusion Health Agenda: The next steps</title><p>In this section, we consider how the current evidence informs policy and practical strategies to advance prevention, diagnosis, clinical care and treatment for people living with HBV infection in groups who have been under-served to date.</p><sec id="s1-4-1"><title>Close the data gap</title><p>There are clear SDG30 goals for HBV, but it is impossible to determine the nature and magnitude of the challenge, benchmark progress, or deploy appropriate interventions without accurate epidemiological data. European Centre for Disease Prevention and Control report major data gaps, now exacerbated by the Covid-19 pandemic, with the worst impact in high-burden (often low income) settings, hampering progress towards elimination (<xref ref-type="bibr" rid="bib97">Pley et al., 2021</xref>). Good quality HBV data for inclusion health populations are lacking, mostly reporting from small, independent, cross sectional seroprevalence studies (summarised in <xref ref-type="table" rid="table2">Table 2</xref>). Unified, transparent data collection will require increased awareness, advocacy, funding and research, with coordination between organisations (e.g. World Health Organization, United States Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control) to help standardise and strengthen approaches. Crucially, evidence is needed to underpin solution-based methods rather than simply describing problems (<xref ref-type="bibr" rid="bib64">Luchenski et al., 2018</xref>; <xref ref-type="bibr" rid="bib109">Siersbaek et al., 2021</xref>).</p></sec><sec id="s1-4-2"><title>Active case finding</title><p>Active targeted screening efforts are an important step towards HBV elimination (<xref ref-type="bibr" rid="bib39">European Centre for Disease Prevention and Control, 2021</xref>; <xref ref-type="bibr" rid="bib61">Lemoine et al., 2015</xref>). Availability of point-of-care hepatitis B surface antigen tests enable community-based diagnosis, although global efforts are needed to prioritise regular supply in resource-constrained settings (<xref ref-type="bibr" rid="bib61">Lemoine et al., 2015</xref>). For migrants, community-based testing strategies are effective, with highest uptake in programmes with endorsement from the local community (<xref ref-type="bibr" rid="bib38">European Centre for Disease Prevention and Control, 2018</xref>; <xref ref-type="bibr" rid="bib101">Robotin and George, 2014</xref>). Outreach screening is equally important in other inclusion health populations, for example, PEH and PWID (<xref ref-type="box" rid="box1">Box 1</xref>). Such outreach screening services have been shown to be feasible and acceptable (<xref ref-type="bibr" rid="bib88">O’Carroll et al., 2017</xref>, <xref ref-type="bibr" rid="bib13">Carr et al., 2014</xref>), and can also be incorporated into other services (e.g. drug harm reduction programmes).</p><boxed-text id="box1"><label>Box 1.</label><caption><title>Case studies of inclusion health interventions.</title></caption><p>1. RESPOND (<xref ref-type="bibr" rid="bib42">Farrant et al., 2022</xref>): RESPOND is a team from University College London Hospitals in the London borough of Camden, providing rapid access community based integrated screening and care planning for asylum seekers. It was formed to accommodate the needs of the rising number of people seeking asylum in temporary accommodation at the beginning of the Covid-19 pandemic. The aim is to provide a multi-disciplinary, comprehensive assessment and formulate an integrated migrant health plan, an electronic document that outlines the key issues for each family member. This document remains with the family, and is copied to the primary healthcare provider, thus removing the need for repeated assessments after each short notice relocation.</p><p>2. Find &amp; Treat (<xref ref-type="bibr" rid="bib121">University College London Hospitals NHS Foundation Trust, 2013</xref>): University College London Hospitals Find &amp; Treat are a specialist outreach team working alongside over 200 NHS and third sector front-line services to tackle TB and blood borne viruses among PEH, PWID, migrants in vulnerable situations or people who have been in prison. The team is multidisciplinary, consisting of people with lived experience working as peer advocates, nurse specialists, social and outreach workers, radiographers, and doctors with primary/secondary care expertise. They use state of the art point of care diagnostics within outreach vans to help overcome barriers in access to care among socially excluded populations.</p><p>3. ‘Gypsy &amp; Traveller Exchange’ (<xref ref-type="bibr" rid="bib60">Leeds gate, 2022</xref>): An example of a successful programme of raising awareness is this programme, led by community members and working in partnership with local services, supported by funding from charitable organisations and local government. Their strategy is to identify community members (or ‘gatekeepers’) who are trusted to facilitate communication with healthcare services, lead cultural awareness training for healthcare workers and provide community outreach and dedicated services for Roma and Traveller populations (<xref ref-type="bibr" rid="bib76">McFadden et al., 2018</xref>; <xref ref-type="bibr" rid="bib20">Condon et al., 2019</xref>; <xref ref-type="bibr" rid="bib13">Carr et al., 2014</xref>). Similar approaches could be successful in other populations to provide education and support.</p><p>4. ‘One Stop Liver Shop’ (<xref ref-type="bibr" rid="bib50">Hla et al., 2020</xref>): The Aboriginal population in the Northern Territory has the highest prevalence of HBV in Australia (6.08% compared to the Non-Indigenous population 1.56%). The ‘One Stop Liver Shop’ was developed iteratively with a very remote Aboriginal community (&gt;500 km from the nearest tertiary hospital in Darwin). It is made up of a specialist doctor, community based Aboriginal Health Practitioner, a sonographer and clinical nurse specialist. They use a portable ultrasound scan, a FibroSan for transient elastography and a mobile device to use the ‘Hep B Story App’, a mobile application using the relevant local language. Visits occur 4 times per year. Due to this initiative, 88% of those aware of their diagnosis were engaged in care and 16% were on treatment.</p></boxed-text><p>All pregnant women should be screened for HBV, and healthcare professionals should consider opportunistically offering HBV screening in high-risk groups accessing services (<xref ref-type="bibr" rid="bib133">World Health Organization, 2020</xref>; <xref ref-type="bibr" rid="bib14">Centers for Disease Control and Prevention, 2022</xref>). There should also be a move to integrate routine hepatitis screening into high-risk healthcare settings, for example TB, sexual health and HIV services. The European Centre for Disease Prevention and Control (ECDC) recommends universal screening in emergency departments in areas where HBV prevalence exceeds 2%, however, evidence suggests that universal emergency department screening is cost effective even at lower prevalence (&gt;0.25%) and therefore the United Kingdom is currently implementing this policy (<xref ref-type="bibr" rid="bib127">Williams et al., 2020b</xref>, <xref ref-type="bibr" rid="bib87">Nebbia et al., 2022</xref>).</p><p>Multiple studies have demonstrated cost-effectiveness of HBV screening in a variety of different scenarios, including community-based outreach and low prevalence settings (<xref ref-type="bibr" rid="bib111">Su et al., 2022</xref>, <xref ref-type="bibr" rid="bib138">Xiao et al., 2020</xref>, <xref ref-type="bibr" rid="bib118">Toy et al., 2022</xref>, <xref ref-type="bibr" rid="bib86">Nayagam et al., 2016</xref>, <xref ref-type="bibr" rid="bib117">Tordrup et al., 2020</xref>, <xref ref-type="bibr" rid="bib53">Hutton et al., 2022</xref>, <xref ref-type="bibr" rid="bib137">Wright et al., 2018</xref>). This is largely due to averting high costs associated with decompensated cirrhosis, HCC and liver transplantation.</p></sec><sec id="s1-4-3"><title>Rethinking prevention strategies</title><p>A safe, effective vaccine against HBV has been available since 1982, and remains a key tool for the elimination of viral hepatitis (<xref ref-type="bibr" rid="bib130">World Health Organization, 2017</xref>). The WHO has recommended a universal birth dose HBV vaccination since 2009, irrespective of the mother’s serological status, but coverage was still only 42% globally and 17% in the WHO African Region by 2021 (<xref ref-type="bibr" rid="bib135">World Health Organization, 2022a</xref>). Modelling suggests that scaling up of a timely birth dose vaccine to &gt;90% by 2030 would result in immediate reduction of chronic HBV incidence, and 710,000 fewer deaths in those born between 2020–2030, globally (<xref ref-type="bibr" rid="bib27">de Villiers et al., 2021</xref>). This strategy would be a particularly important public health intervention for future inclusion health populations, in whom catch-up three-dose adult vaccination is challenging and may not be cost-effective.</p><p>While catch-up adult vaccination is not advocated at a general population level, opportunities for providing vaccination to high-risk adults must still be explored and developed, optimising approaches to deliver a three-dose schedule alongside education, proactive antenatal and sexual healthcare, and other health interventions (<xref ref-type="box" rid="box2">Box 2</xref>).</p><boxed-text id="box2"><label>Box 2.</label><caption><title>Example methods of increasing HBV vaccination coverage among high-risk groups</title></caption><list list-type="order"><list-item><p>Universal HBV vaccination in prisons in Scotland (<xref ref-type="bibr" rid="bib94">Palmateer et al., 2018</xref>).</p><list list-type="bullet"><list-item><p>Following prison-related outbreaks of acute HBV among PWID, HBV vaccination for all prisoners was introduced in 1999.</p></list-item><list-item><p>Among recent-onset PWID in Glasgow, vaccine uptake increased from 16% in 1993 to 59% in 2009–2014 (p&lt;0.001).</p></list-item><list-item><p>HBsAg prevalence 0.3% among people who commenced injecting drugs in the decade since universal vaccination induced, compared to 9% globally.</p></list-item><list-item><p>Vaccination is associated with 40% reduced odds of ever having HBV (aOR = 0.6, 95% CI 0.37–0.97).</p></list-item></list></list-item><list-item><p>HBV-COMSAVA (Community Screening and Vaccination in Africans) Study, Barcelona, Spain (<xref ref-type="bibr" rid="bib95">Picchio et al., 2021</xref>).</p><list list-type="bullet"><list-item><p>Pop-up clinics at west African migrant faith-based and community organisations.</p></list-item><list-item><p>Individuals offered a rapid HBsAg diagnostic test and a dried blood sample for analysing HBV viral load and co-infection with hepatitis D virus.</p></list-item><list-item><p>If HBsAg +, same day referral to specialist with expedited referral process which did not require prior appointment.</p></list-item><list-item><p>If susceptible, offered HBV vaccine in situ at return appointment (‘return-date slip’ reminder given at first appointment).</p></list-item><list-item><p>70% were susceptible to HBV, 74% returned to receive results and 86% of those who returned accepted vaccination.</p></list-item></list></list-item><list-item><p>Sex-worker outreach, Ghent, Belgium (<xref ref-type="bibr" rid="bib69">Mak et al., 2003</xref>)</p><list list-type="bullet"><list-item><p>A medical doctor and social nurse visited the workplaces of sex-workers, discussed professional risks, handed out prevention materials and offered free STI screening (Chlamydia, gonorrhoea, syphilis, HIV), a cervical smear and free HBV vaccination.</p></list-item><list-item><p>Psychological and legal programs related to sex work could also be discussed and anonymity guaranteed.</p></list-item><list-item><p>Over two-thirds of susceptible sex-workers completed an accelerated HBV vaccination schedule (over 2 months), compared to less than half if given over 6 months.</p></list-item><list-item><p>Only 7% were vaccinated in existing services.</p></list-item></list></list-item></list></boxed-text><p>Given the slow and heterogenous uptake of birth dose vaccination, and challenges associated with catch-up vaccination of inclusion health populations, other prevention strategies need urgent consideration. For example, the ‘Test and Treat’ strategy which aims to suppress the reservoir of virus in the population (<xref ref-type="bibr" rid="bib77">McNaughton et al., 2019</xref>). According to current guidelines, only 25–35% of adults with CHB are eligible for treatment, leaving the majority at risk of both longer term complications (relevant to the individual) and the potential for transmission (relevant to populations) (<xref ref-type="bibr" rid="bib78">McNaughton et al., 2021</xref>). HBV/HIV co-infected individuals may have a treatment advantage, reflecting the benefits of greater access to early and consistent antiviral treatment compared to mono-infected individuals (<xref ref-type="bibr" rid="bib70">Maponga et al., 2020</xref>). Potential risks should be considered: toxicity and side effects, requirement for monitoring, potential for drug resistance, limited gains from treating well people and the cost of drug and potential diversion of healthcare resources (<xref ref-type="bibr" rid="bib78">McNaughton et al., 2021</xref>). Further research is required to assess the efficacy, feasibility and acceptability of wider treatment roll out.</p></sec><sec id="s1-4-4"><title>Designing inclusive HBV healthcare</title><p>Once diagnosed, HBV requires long-term surveillance. However, current models of healthcare fail to provide adequate continuity for inclusion health populations, and innovative solutions are needed. Interventions to reduce the burden of vaccine-preventable infections among migrants can be classified based on the <italic>individual</italic>, <italic>community</italic>, <italic>provider</italic> and <italic>system</italic> (<xref ref-type="bibr" rid="bib16">Charania et al., 2020</xref>). This framework can be applied to all inclusion health populations (<xref ref-type="box" rid="box2">Box 2</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Solutions for service development to overcome barriers for people living with hepatitis B virus (HBV) infection in inclusion health populations, applying framework suggested by <xref ref-type="bibr" rid="bib16">Charania et al., 2020</xref>.</title><p>Figure created in <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">BioRender.com</ext-link> with a licence to publish.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81070-fig2-v1.tif"/></fig></sec><sec id="s1-4-5"><title>Developing holistic approaches</title><p>Inclusion health populations face many challenges; therefore, the HBV agenda must not operate in a silo. Integrated infectious disease screening can be cost-effective and an efficient use of resources. An example is the World Health Organization’s ‘triple elimination initiative’ which encourages countries to simultaneously commit to elimination of mother-to-child transmission of HIV, syphilis and HBV (<xref ref-type="bibr" rid="bib136">World Health Organization, 2022b</xref>). This approach has been demonstrated to reduce disease transmission rates, staff and patient time, and overall programme cost (<xref ref-type="bibr" rid="bib140">Zhang et al., 2019</xref>).</p><p>Integrated infection screening is also recommended in migrants, and in most countries screening tests are offered following a risk assessment (<xref ref-type="bibr" rid="bib38">European Centre for Disease Prevention and Control, 2018</xref>). Screening is found to be cost-effective, feasible and acceptable, but migrants are a heterogenous group, and services should be culturally appropriate, and accommodate the possibility of fear and stigma surrounding screening and diagnosis (<xref ref-type="bibr" rid="bib107">Seedat et al., 2018</xref>; <xref ref-type="bibr" rid="bib17">Cinardo et al., 2022</xref>). In many countries, migrants will undergo pre-entry or port-of-entry screening, missing those who arrive through informal routes (<xref ref-type="bibr" rid="bib17">Cinardo et al., 2022</xref>). Culturally sensitive outreach services are an important way to reach and screen inclusion health populations (<xref ref-type="box" rid="box1">Box 1</xref>).</p><p>Multi-morbidity is common, for example, incarcerated individuals with HBV have high rates of HIV, HCV and /or TB co-infection (<xref ref-type="bibr" rid="bib2">Ahmadi Gharaei et al., 2021</xref>; <xref ref-type="bibr" rid="bib30">do Nascimento et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">La Torre et al., 2007</xref>), and of substance use and severe mental illness (<xref ref-type="bibr" rid="bib56">Kamarulzaman et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Fazel and Danesh, 2002</xref>). Non-communicable diseases are also prevalent among inclusion health populations (<xref ref-type="bibr" rid="bib119">Tweed et al., 2021</xref>) for example, PEH have a three-fold elevated risk of cardiovascular disease and cardiovascular mortality compared to non-homeless individuals (<xref ref-type="table" rid="table2">Table 2</xref>; <xref ref-type="bibr" rid="bib4">Al Shakarchi et al., 2020</xref>). Moreover, people with co-existing exposures, for example incarceration and substance use, or serious mental illness and substance use, have worse outcomes (<xref ref-type="bibr" rid="bib119">Tweed et al., 2021</xref>). Diabetes is associated with an increased risk of HBV-associated HCC (hazard ratio 1.36, 95% CI 1.23–1.49)(<xref ref-type="bibr" rid="bib12">Campbell et al., 2021</xref>). The HBV inclusion health agenda must therefore take a ‘syndemic’ approach, namely to tackle viral hepatitis not as an isolated challenge but recognising its place amongst complex social, physical and mental health challenges and addressing the person as a whole (<xref ref-type="bibr" rid="bib79">Mendenhall, 2017</xref>; <xref ref-type="bibr" rid="bib73">Matthews et al., 2022b</xref>).</p></sec><sec id="s1-4-6"><title>Prioritising patient and public involvement</title><p>HBV infection can result in stigma and discrimination, which is magnified when combined with the experiences of socially excluded groups (<xref ref-type="bibr" rid="bib72">Matthews et al., 2022a</xref>). Sharing lived experiences builds rapport, trust and equality, helping promote advocacy, build peer support networks, navigate healthcare systems and promote diagnosis and treatment of blood borne infections (<xref ref-type="bibr" rid="bib93">Paisi et al., 2022</xref>; <xref ref-type="bibr" rid="bib24">Crone et al., 2022</xref>). There is a long history of peer-led approaches with successful outcomes in HIV, TB and HCV (<xref ref-type="bibr" rid="bib110">Story et al., 2020</xref>; <xref ref-type="bibr" rid="bib89">Øgård-Repål et al., 2023</xref>). For example, as part of the HepCare project, people with lived experience of HCV infection were upskilled to become equal members of the healthcare team, providing a cost-effective approach to enhancing diagnosis, linkage to care and treatment success (<xref ref-type="bibr" rid="bib124">Ward et al., 2019</xref>; <xref ref-type="bibr" rid="bib113">Surey et al., 2021</xref>; <xref ref-type="bibr" rid="bib112">Surey et al., 2019</xref>). Importantly, a focus group involving people with lived experience ranked advocacy via peer-led services as the second most important intervention behind stable housing (<xref ref-type="bibr" rid="bib64">Luchenski et al., 2018</xref>). The success and knowledge gained from this peer-led approach must now be translated to HBV.</p></sec><sec id="s1-4-7"><title>Improving awareness, education, and advocacy</title><p>Qualitative research from Australia has identified lack of confidence of healthcare professionals and poor communication surrounding HBV (<xref ref-type="bibr" rid="bib123">Wallace et al., 2011</xref>; <xref ref-type="bibr" rid="bib102">Robotin et al., 2021</xref>). Sensitive communication around HBV is of heightened importance in populations who already experience discrimination and stigma, and is a particular consideration where certain subjects are culturally taboo (<xref ref-type="bibr" rid="bib20">Condon et al., 2019</xref>). Engagement requires sensitivity to cultural nuances, including traditional and religious beliefs (<xref ref-type="bibr" rid="bib51">Holmstrom, 2019</xref>, <xref ref-type="bibr" rid="bib13">Carr et al., 2014</xref>). Training for healthcare professionals in trauma-informed care would benefit many inclusion health populations who are more likely to have a history of experiencing assault and torture (<xref ref-type="bibr" rid="bib35">Emily, 2021</xref>). Lack of awareness is present in healthcare professionals as well as in at-risk populations (<xref ref-type="bibr" rid="bib18">Cochrane et al., 2016</xref>; <xref ref-type="bibr" rid="bib8">Bierhoff et al., 2021</xref>). A UK survey of primary care practitioners found many did not believe routine testing of HBV in migrants was necessary, and national guidelines were poorly followed (<xref ref-type="bibr" rid="bib40">Evlampidou et al., 2016</xref>). Interventions to raise HBV awareness in different groups are paramount to inform action for inclusion health populations.</p></sec><sec id="s1-4-8"><title>Representative research</title><p>Inclusion health populations are often seen as ‘hard to reach’ and may not be viewed as ideal research participants given the possibility of increased loss to follow up and co-morbid conditions. This is further exacerbated in low-resource settings, where there is higher HBV prevalence. There is a striking lack of inclusion health research within Africa, even among global reviews (<xref ref-type="table" rid="table2">Table 2</xref>). In order to be generalisable and equitable, HBV research needs to be representative of real-world populations and challenges, on a global scale. Performance of new biomarkers, for example hepatitis B core-related antigen, or clinical fibrosis scores, such as APRI and FIB-4, needs to be validated for clinical utility in these populations with overlapping risk factors, multi-morbidity and in varying global populations. While limited treatments currently exist for HBV infection, there is active research into improved treatment and curative therapies; for these to be relevant in populations most affected by HBV, clinical trials must recruit accordingly. Mixed-method approaches should be utilised to understand views and unmet needs of marginalised communities in relation to HBV. The exclusion of inclusion health populations from the current research agenda is likely to further exacerbate inequities when more effective treatments do become available.</p></sec></sec><sec id="s1-5"><title>Conclusion</title><p>Inclusion health populations comprise diverse groups, but share common experiences including stigma, discrimination, marginalisation, and barriers to accessing diagnostic services and engaging with long-term care. There is a disproportionate impact of HBV among these populations, both caused and exacerbated by social exclusion, which is associated with increased morbidity and mortality. These challenges are even greater in resource-limited settings, where HBV burden is higher but robust data are lacking.</p><p>The power and impact of existing studies representing HBV in these populations are limited by small size, cross sectional design and heterogeneity. There are few investigations into interventions, scarce qualitative data, and limited representation of people with lived experience. Moreover, patient advocacy groups for HBV, particularly in inclusion health populations, do not have the same presence or traction as for other infectious diseases, for example TB or HIV. More well-designed prospective studies are needed to allow investigation of the complex interplay between social adversity, co-morbidity and HBV infection to better understand its epidemiology, risk factors, pathogenesis and outcomes within under-served populations. Representative research is crucial to ensure that new discoveries, for example treatments, biomarkers and risk scores, are equitable, relevant, applicable and accessible to the populations where they are most relevant, while qualitative research is needed to understand the perspectives and priorities of the HBV community and inform more effective messaging and advocacy. Innovative methods are urgently required to overcome barriers, adapt healthcare and create services that are fit-for-purpose for inclusion health populations, integrating HBV care into holistic strategies that provide interdisciplinary care to address the complex overlapping needs of inclusion health populations. HBV epitomises the need to adopt a syndemic approach that recognises and addresses the complex interplay between comorbidity and sociocultural contexts.</p></sec></sec></body><back><sec sec-type="additional-information" id="s2"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>MB has led local research studies funded by Gilead (an HIV testing study in 2009 or so, and COVID trials 2020-22) and has provided (unfunded) consultancy to Gilead wrt COVID therapeutics</p></fn><fn fn-type="COI-statement" id="conf4"><p>CI has received support for conference attendance and research grant paid to his institution from Gilead Sciences Ltd</p></fn><fn fn-type="COI-statement" id="conf5"><p>SF has received travel and conference bursaries from AbbVie, Gilead, Bristol-Myers-Squibb, IMS Health</p></fn><fn fn-type="COI-statement" id="conf6"><p>PCM holds a Wellcome Fellowship and NIHR funding, and receives funding to her research team from GSK</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Supervision, Funding acquisition, Visualization, Writing – original draft, Project administration</p></fn></fn-group></sec><ack id="ack"><title>Acknowledgements</title><p>PCM is funded by Wellcome (grant ref 110110/Z/15/Z), UCLH NIHR Biomedical Research Centre, and the Francis Crick Institute. AS is Clinical Lead for UCLH Find&amp;Treat Service and UCL Professor of Inclusion Health. EM is an NIHR funded academic clinical fellow. BS receives doctoral funding from NIHR.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adjei</surname><given-names>CA</given-names></name><name><surname>Stutterheim</surname><given-names>SE</given-names></name><name><surname>Naab</surname><given-names>F</given-names></name><name><surname>Ruiter</surname><given-names>RAC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Barriers to chronic hepatitis B treatment and care in ghana: a qualitative study with people with hepatitis B and healthcare providers</article-title><source>PLOS ONE</source><volume>14</volume><elocation-id>e0225830</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0225830</pub-id><pub-id pub-id-type="pmid">31794577</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmadi Gharaei</surname><given-names>H</given-names></name><name><surname>Fararouei</surname><given-names>M</given-names></name><name><surname>Mirzazadeh</surname><given-names>A</given-names></name><name><surname>Sharifnia</surname><given-names>G</given-names></name><name><surname>Rohani-Rasaf</surname><given-names>M</given-names></name><name><surname>Bastam</surname><given-names>D</given-names></name><name><surname>Rahimi</surname><given-names>J</given-names></name><name><surname>Kouhestani</surname><given-names>M</given-names></name><name><surname>Rezaian</surname><given-names>S</given-names></name><name><surname>Dianatinasab</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The global and regional prevalence of hepatitis C and B co-infections among prisoners living with HIV: a systematic review and meta-analysis</article-title><source>Infectious Diseases of Poverty</source><volume>10</volume><elocation-id>93</elocation-id><pub-id pub-id-type="doi">10.1186/s40249-021-00876-7</pub-id><pub-id pub-id-type="pmid">34210349</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldridge</surname><given-names>RW</given-names></name><name><surname>Story</surname><given-names>A</given-names></name><name><surname>Hwang</surname><given-names>SW</given-names></name><name><surname>Nordentoft</surname><given-names>M</given-names></name><name><surname>Luchenski</surname><given-names>SA</given-names></name><name><surname>Hartwell</surname><given-names>G</given-names></name><name><surname>Tweed</surname><given-names>EJ</given-names></name><name><surname>Lewer</surname><given-names>D</given-names></name><name><surname>Vittal Katikireddi</surname><given-names>S</given-names></name><name><surname>Hayward</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis</article-title><source>Lancet</source><volume>391</volume><fpage>241</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31869-X</pub-id><pub-id pub-id-type="pmid">29137869</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Shakarchi</surname><given-names>NJ</given-names></name><name><surname>Evans</surname><given-names>H</given-names></name><name><surname>Luchenski</surname><given-names>SA</given-names></name><name><surname>Story</surname><given-names>A</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cardiovascular disease in homeless versus housed individuals: a systematic review of observational and interventional studies</article-title><source>Heart</source><volume>106</volume><fpage>1483</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2020-316706</pub-id><pub-id pub-id-type="pmid">32665359</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arasteh</surname><given-names>K</given-names></name><name><surname>Des Jarlais</surname><given-names>DC</given-names></name><name><surname>Perlis</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Alcohol and HIV sexual risk behaviors among injection drug users</article-title><source>Drug and Alcohol Dependence</source><volume>95</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2007.12.008</pub-id><pub-id pub-id-type="pmid">18242009</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armitage</surname><given-names>AJ</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Heys</surname><given-names>M</given-names></name><name><surname>Hardelid</surname><given-names>P</given-names></name><name><surname>Ward</surname><given-names>A</given-names></name><name><surname>Eisen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Description and evaluation of a pathway for unaccompanied asylum-seeking children</article-title><source>Archives of Disease in Childhood</source><volume>107</volume><fpage>456</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2021-322319</pub-id><pub-id pub-id-type="pmid">34656979</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>JN</given-names></name><name><surname>Foli</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Health-seeking behaviours in the homeless population: a concept analysis</article-title><source>Health &amp; Social Care in the Community</source><volume>30</volume><fpage>e278</fpage><lpage>e286</lpage><pub-id pub-id-type="doi">10.1111/hsc.13499</pub-id><pub-id pub-id-type="pmid">34250681</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bierhoff</surname><given-names>M</given-names></name><name><surname>Hashmi</surname><given-names>AH</given-names></name><name><surname>Pateekhum</surname><given-names>C</given-names></name><name><surname>Jiraporncharoen</surname><given-names>W</given-names></name><name><surname>Wiwattanacharoen</surname><given-names>W</given-names></name><name><surname>Paw</surname><given-names>MK</given-names></name><name><surname>Nosten</surname><given-names>FH</given-names></name><name><surname>Rijken</surname><given-names>MJ</given-names></name><name><surname>Van Vugt</surname><given-names>M</given-names></name><name><surname>McGready</surname><given-names>R</given-names></name><name><surname>Angkurawaranon</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A mixed-methods evaluation of hepatitis B knowledge, attitudes, and practices among migrant women in thailand</article-title><source>BMC Pregnancy and Childbirth</source><volume>21</volume><elocation-id>525</elocation-id><pub-id pub-id-type="doi">10.1186/s12884-021-03914-2</pub-id><pub-id pub-id-type="pmid">34301179</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binswanger</surname><given-names>IA</given-names></name><name><surname>Stern</surname><given-names>MF</given-names></name><name><surname>Deyo</surname><given-names>RA</given-names></name><name><surname>Heagerty</surname><given-names>PJ</given-names></name><name><surname>Cheadle</surname><given-names>A</given-names></name><name><surname>Elmore</surname><given-names>JG</given-names></name><name><surname>Koepsell</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Release from prison -- a high risk of death for former inmates</article-title><source>The New England Journal of Medicine</source><volume>356</volume><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1056/NEJMsa064115</pub-id><pub-id pub-id-type="pmid">17215533</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bitty-Anderson</surname><given-names>AM</given-names></name><name><surname>Ferré</surname><given-names>V</given-names></name><name><surname>Gbeasor-Komlanvi</surname><given-names>FA</given-names></name><name><surname>Tchankoni</surname><given-names>MK</given-names></name><name><surname>Sadio</surname><given-names>A</given-names></name><name><surname>Salou</surname><given-names>M</given-names></name><name><surname>Descamps</surname><given-names>D</given-names></name><name><surname>Dagnra</surname><given-names>CA</given-names></name><name><surname>Charpentier</surname><given-names>C</given-names></name><name><surname>Ekouevi</surname><given-names>DK</given-names></name><name><surname>Coffie</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Prevalence of hepatitis B and C among female sex workers in togo, west africa</article-title><source>PLOS ONE</source><volume>16</volume><elocation-id>e0259891</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0259891</pub-id><pub-id pub-id-type="pmid">34890388</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>Goulder</surname><given-names>P</given-names></name><name><surname>Matthews</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Sexual dimorphism in chronic hepatitis B virus (HBV) infection: evidence to inform elimination efforts</article-title><source>Wellcome Open Research</source><volume>7</volume><elocation-id>32</elocation-id><pub-id pub-id-type="doi">10.12688/wellcomeopenres.17601.2</pub-id><pub-id pub-id-type="pmid">36212217</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>McNaughton</surname><given-names>AL</given-names></name><name><surname>Barnes</surname><given-names>E</given-names></name><name><surname>Matthews</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis</article-title><source>Journal of Viral Hepatitis</source><volume>28</volume><fpage>493</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1111/jvh.13452</pub-id><pub-id pub-id-type="pmid">33305479</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>SM</given-names></name><name><surname>Lhussier</surname><given-names>M</given-names></name><name><surname>Forster</surname><given-names>N</given-names></name><name><surname>Goodall</surname><given-names>D</given-names></name><name><surname>Geddes</surname><given-names>L</given-names></name><name><surname>Pennington</surname><given-names>M</given-names></name><name><surname>Bancroft</surname><given-names>A</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Michie</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Outreach programmes for health improvement of traveller communities: a synthesis of evidence</article-title><source>Public Health Research</source><volume>2</volume><fpage>1</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.3310/phr02030</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Hepatitis B Questions and Answers for Health Professionals</article-title><ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm">https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm</ext-link><date-in-citation iso-8601-date="2022-11-18">November 18, 2022</date-in-citation></element-citation></ref><ref id="bib15"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Chamie</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>As Cities Grow, So Do the Numbers of Homeless</article-title><source>Yale University Macmillan Center</source><ext-link ext-link-type="uri" xlink:href="https://archive-yaleglobal.yale.edu/content/cities-grow-so-do-numbers-homeless">https://archive-yaleglobal.yale.edu/content/cities-grow-so-do-numbers-homeless</ext-link><date-in-citation iso-8601-date="2020-08-22">August 22, 2020</date-in-citation></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charania</surname><given-names>NA</given-names></name><name><surname>Gaze</surname><given-names>N</given-names></name><name><surname>Kung</surname><given-names>JY</given-names></name><name><surname>Brooks</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Interventions to reduce the burden of vaccine-preventable diseases among migrants and refugees worldwide: a scoping review of published literature, 2006-2018</article-title><source>Vaccine</source><volume>38</volume><fpage>7217</fpage><lpage>7225</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.09.054</pub-id><pub-id pub-id-type="pmid">33008670</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinardo</surname><given-names>P</given-names></name><name><surname>Farrant</surname><given-names>O</given-names></name><name><surname>Gunn</surname><given-names>K</given-names></name><name><surname>Ward</surname><given-names>A</given-names></name><name><surname>Eisen</surname><given-names>S</given-names></name><name><surname>Longley</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Screening for neglected tropical diseases and other infections in refugee and asylum-seeker populations in the united kingdom</article-title><source>Therapeutic Advances in Infectious Disease</source><volume>9</volume><elocation-id>20499361221116680</elocation-id><pub-id pub-id-type="doi">10.1177/20499361221116680</pub-id><pub-id pub-id-type="pmid">35958977</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cochrane</surname><given-names>A</given-names></name><name><surname>Collins</surname><given-names>P</given-names></name><name><surname>Horwood</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Barriers and opportunities for hepatitis B testing and contact tracing in a UK somali population: a qualitative study</article-title><source>European Journal of Public Health</source><volume>26</volume><fpage>389</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1093/eurpub/ckv236</pub-id><pub-id pub-id-type="pmid">26896472</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colucci</surname><given-names>G</given-names></name><name><surname>Uceda Renteria</surname><given-names>S</given-names></name><name><surname>Lunghi</surname><given-names>G</given-names></name><name><surname>Ceriotti</surname><given-names>F</given-names></name><name><surname>Sguazzini</surname><given-names>E</given-names></name><name><surname>Spalenza</surname><given-names>S</given-names></name><name><surname>Regazzo</surname><given-names>C</given-names></name><name><surname>Lampertico</surname><given-names>P</given-names></name><name><surname>Colombo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Italian migrants study: an HCV and HBV micro-elimination pilot project</article-title><source>Clinics and Research in Hepatology and Gastroenterology</source><volume>46</volume><elocation-id>101852</elocation-id><pub-id pub-id-type="doi">10.1016/j.clinre.2021.101852</pub-id><pub-id pub-id-type="pmid">34923181</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Condon</surname><given-names>L</given-names></name><name><surname>Bedford</surname><given-names>H</given-names></name><name><surname>Ireland</surname><given-names>L</given-names></name><name><surname>Kerr</surname><given-names>S</given-names></name><name><surname>Mytton</surname><given-names>J</given-names></name><name><surname>Richardson</surname><given-names>Z</given-names></name><name><surname>Jackson</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Engaging gypsy, roma, and traveller communities in research: maximizing opportunities and overcoming challenges</article-title><source>Qualitative Health Research</source><volume>29</volume><fpage>1324</fpage><lpage>1333</lpage><pub-id pub-id-type="doi">10.1177/1049732318813558</pub-id><pub-id pub-id-type="pmid">30600758</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooke</surname><given-names>GS</given-names></name><name><surname>Andrieux-Meyer</surname><given-names>I</given-names></name><name><surname>Applegate</surname><given-names>TL</given-names></name><name><surname>Atun</surname><given-names>R</given-names></name><name><surname>Burry</surname><given-names>JR</given-names></name><name><surname>Cheinquer</surname><given-names>H</given-names></name><name><surname>Dusheiko</surname><given-names>G</given-names></name><name><surname>Feld</surname><given-names>JJ</given-names></name><name><surname>Gore</surname><given-names>C</given-names></name><name><surname>Griswold</surname><given-names>MG</given-names></name><name><surname>Hamid</surname><given-names>S</given-names></name><name><surname>Hellard</surname><given-names>ME</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Howell</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Kravchenko</surname><given-names>N</given-names></name><name><surname>Lazarus</surname><given-names>JV</given-names></name><name><surname>Lemoine</surname><given-names>M</given-names></name><name><surname>Lesi</surname><given-names>OA</given-names></name><name><surname>Maistat</surname><given-names>L</given-names></name><name><surname>McMahon</surname><given-names>BJ</given-names></name><name><surname>Razavi</surname><given-names>H</given-names></name><name><surname>Roberts</surname><given-names>T</given-names></name><name><surname>Simmons</surname><given-names>B</given-names></name><name><surname>Sonderup</surname><given-names>MW</given-names></name><name><surname>Spearman</surname><given-names>CW</given-names></name><name><surname>Taylor</surname><given-names>BE</given-names></name><name><surname>Thomas</surname><given-names>DL</given-names></name><name><surname>Waked</surname><given-names>I</given-names></name><name><surname>Ward</surname><given-names>JW</given-names></name><name><surname>Wiktor</surname><given-names>SZ</given-names></name><collab>Lancet Gastroenterology &amp; Hepatology Commissioners</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Accelerating the elimination of viral hepatitis: a lancet gastroenterology &amp; hepatology commission</article-title><source>The Lancet. Gastroenterology &amp; Hepatology</source><volume>4</volume><fpage>135</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(18)30270-X</pub-id><pub-id pub-id-type="pmid">30647010</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>M</given-names></name><name><surname>Barré</surname><given-names>T</given-names></name><name><surname>Coste</surname><given-names>M</given-names></name><name><surname>Yaya</surname><given-names>I</given-names></name><name><surname>Berenger</surname><given-names>C</given-names></name><name><surname>Tanti</surname><given-names>M</given-names></name><name><surname>Cutarella</surname><given-names>C</given-names></name><name><surname>Mora</surname><given-names>M</given-names></name><name><surname>Poloméni</surname><given-names>P</given-names></name><name><surname>Maynard</surname><given-names>M</given-names></name><name><surname>Teuma</surname><given-names>D</given-names></name><name><surname>Bazin</surname><given-names>M</given-names></name><name><surname>Maradan</surname><given-names>G</given-names></name><name><surname>Roux</surname><given-names>P</given-names></name><name><surname>Carrieri</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Screening and care for alcohol use disorder in france: expectations, barriers and levers using a mixed-methods approach</article-title><source>BMC Public Health</source><volume>20</volume><elocation-id>358</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-020-08495-x</pub-id><pub-id pub-id-type="pmid">32188436</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="report"><person-group person-group-type="author"><collab>Council of Europe</collab></person-group><year iso-8601-date="2020">2020</year><source>Council of Europe Strategic Action Plan for Roma and Traveller Inclusion (2020 - 2025)</source><publisher-name>Council of Europe</publisher-name></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crone</surname><given-names>B</given-names></name><name><surname>Metraux</surname><given-names>S</given-names></name><name><surname>Sbrocco</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Health service access among homeless veterans: health access challenges faced by homeless African American veterans</article-title><source>Journal of Racial and Ethnic Health Disparities</source><volume>9</volume><fpage>1828</fpage><lpage>1844</lpage><pub-id pub-id-type="doi">10.1007/s40615-021-01119-z</pub-id><pub-id pub-id-type="pmid">34402040</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dana</surname><given-names>D</given-names></name><name><surname>Zary</surname><given-names>N</given-names></name><name><surname>Peyman</surname><given-names>A</given-names></name><name><surname>Behrooz</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Risk prison and hepatitis B virus infection among inmates with history of drug injection in isfahan, iran</article-title><source>TheScientificWorldJournal</source><volume>2013</volume><elocation-id>735761</elocation-id><pub-id pub-id-type="doi">10.1155/2013/735761</pub-id><pub-id pub-id-type="pmid">23737725</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>EL</given-names></name><name><surname>Littlejohn</surname><given-names>M</given-names></name><name><surname>Edwards</surname><given-names>R</given-names></name><name><surname>Sozzi</surname><given-names>V</given-names></name><name><surname>Jackson</surname><given-names>K</given-names></name><name><surname>Mcguire</surname><given-names>K</given-names></name><name><surname>Binks</surname><given-names>P</given-names></name><name><surname>Cowie</surname><given-names>BC</given-names></name><name><surname>Locarnini</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>JS</given-names></name><name><surname>Tong</surname><given-names>SYC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Towards genotype-specific care for chronic hepatitis B: the first 6 years follow up from the CHARM cohort study</article-title><source>Open Forum Infectious Diseases</source><volume>6</volume><elocation-id>fz469</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofz469</pub-id><pub-id pub-id-type="pmid">32864387</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Villiers</surname><given-names>MJ</given-names></name><name><surname>Nayagam</surname><given-names>S</given-names></name><name><surname>Hallett</surname><given-names>TB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The impact of the timely birth dose vaccine on the global elimination of hepatitis B</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>6223</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-26475-6</pub-id><pub-id pub-id-type="pmid">34711822</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degenhardt</surname><given-names>L</given-names></name><name><surname>Peacock</surname><given-names>A</given-names></name><name><surname>Colledge</surname><given-names>S</given-names></name><name><surname>Leung</surname><given-names>J</given-names></name><name><surname>Grebely</surname><given-names>J</given-names></name><name><surname>Vickerman</surname><given-names>P</given-names></name><name><surname>Stone</surname><given-names>J</given-names></name><name><surname>Cunningham</surname><given-names>EB</given-names></name><name><surname>Trickey</surname><given-names>A</given-names></name><name><surname>Dumchev</surname><given-names>K</given-names></name><name><surname>Lynskey</surname><given-names>M</given-names></name><name><surname>Griffiths</surname><given-names>P</given-names></name><name><surname>Mattick</surname><given-names>RP</given-names></name><name><surname>Hickman</surname><given-names>M</given-names></name><name><surname>Larney</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review</article-title><source>The Lancet. Global Health</source><volume>5</volume><fpage>e1192</fpage><lpage>e1207</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(17)30375-3</pub-id><pub-id pub-id-type="pmid">29074409</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolan</surname><given-names>K</given-names></name><name><surname>Wirtz</surname><given-names>AL</given-names></name><name><surname>Moazen</surname><given-names>B</given-names></name><name><surname>Ndeffo-Mbah</surname><given-names>M</given-names></name><name><surname>Galvani</surname><given-names>A</given-names></name><name><surname>Kinner</surname><given-names>SA</given-names></name><name><surname>Courtney</surname><given-names>R</given-names></name><name><surname>McKee</surname><given-names>M</given-names></name><name><surname>Amon</surname><given-names>JJ</given-names></name><name><surname>Maher</surname><given-names>L</given-names></name><name><surname>Hellard</surname><given-names>M</given-names></name><name><surname>Beyrer</surname><given-names>C</given-names></name><name><surname>Altice</surname><given-names>FL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees</article-title><source>Lancet</source><volume>388</volume><fpage>1089</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)30466-4</pub-id><pub-id pub-id-type="pmid">27427453</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>do Nascimento</surname><given-names>CT</given-names></name><name><surname>Pena</surname><given-names>DZ</given-names></name><name><surname>Giuffrida</surname><given-names>R</given-names></name><name><surname>Bandeira Monteiro</surname><given-names>FN</given-names></name><name><surname>da Silva</surname><given-names>FA</given-names></name><name><surname>Flores</surname><given-names>EF</given-names></name><name><surname>Prestes-Carneiro</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Prevalence and epidemiological characteristics of inmates diagnosed with infectious diseases living in a region with a high number of prisons in São Paulo state, Brazil</article-title><source>BMJ Open</source><volume>10</volume><elocation-id>e037045</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2020-037045</pub-id><pub-id pub-id-type="pmid">32895275</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dos Ramos Farías</surname><given-names>MS</given-names></name><name><surname>Garcia</surname><given-names>MN</given-names></name><name><surname>Reynaga</surname><given-names>E</given-names></name><name><surname>Romero</surname><given-names>M</given-names></name><name><surname>Vaulet</surname><given-names>MLG</given-names></name><name><surname>Fermepín</surname><given-names>MR</given-names></name><name><surname>Toscano</surname><given-names>MF</given-names></name><name><surname>Rey</surname><given-names>J</given-names></name><name><surname>Marone</surname><given-names>R</given-names></name><name><surname>Squiquera</surname><given-names>L</given-names></name><name><surname>González</surname><given-names>JV</given-names></name><name><surname>Basiletti</surname><given-names>J</given-names></name><name><surname>Picconi</surname><given-names>MA</given-names></name><name><surname>Pando</surname><given-names>MA</given-names></name><name><surname>Avila</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>First report on sexually transmitted infections among trans (male to female transvestites, transsexuals, or transgender) and male sex workers in argentina: high HIV, HPV, HBV, and syphilis prevalence</article-title><source>International Journal of Infectious Diseases</source><volume>15</volume><fpage>e635</fpage><lpage>e640</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2011.05.007</pub-id><pub-id pub-id-type="pmid">21742530</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duby</surname><given-names>Z</given-names></name><name><surname>Nkosi</surname><given-names>B</given-names></name><name><surname>Scheibe</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>B</given-names></name><name><surname>Bekker</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>“ Scared of going to the clinic”: contextualising healthcare access for men who have sex with men, female sex workers and people who use drugs in two south african cities</article-title><source>Southern African Journal of HIV Medicine</source><volume>19</volume><elocation-id>701</elocation-id><pub-id pub-id-type="doi">10.4102/sajhivmed.v19i1.701</pub-id><pub-id pub-id-type="pmid">29568645</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eborall</surname><given-names>H</given-names></name><name><surname>Wobi</surname><given-names>F</given-names></name><name><surname>Ellis</surname><given-names>K</given-names></name><name><surname>Willars</surname><given-names>J</given-names></name><name><surname>Abubakar</surname><given-names>I</given-names></name><name><surname>Griffiths</surname><given-names>C</given-names></name><name><surname>Pareek</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Integrated screening of migrants for multiple infectious diseases: qualitative study of a city-wide programme</article-title><source>EClinicalMedicine</source><volume>21</volume><fpage>100315</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2020.100315</pub-id><pub-id pub-id-type="pmid">32322806</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Einsiedel</surname><given-names>L</given-names></name><name><surname>Fernandes</surname><given-names>L</given-names></name><name><surname>Joseph</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Woodman</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Non-Communicable diseases, infection and survival in a retrospective cohort of Indigenous and non-Indigenous adults in central Australia</article-title><source>BMJ Open</source><volume>3</volume><elocation-id>e003070</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2013-003070</pub-id><pub-id pub-id-type="pmid">23872293</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Emily</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><chapter-title>Clinics for migrant and refugee children: psychosocial and organizational considerations</chapter-title><person-group person-group-type="editor"><name><surname>Esmaili</surname><given-names>E</given-names></name></person-group><source>Child Refugee and Migrant Health: A Manual for Health Professionals</source><publisher-loc>Switzerland</publisher-loc><publisher-name>Springer Nature</publisher-name><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-74906-4_10</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Equality and Human Rights Commission</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Gypsies and Travellers: simple solutions for living together</article-title><ext-link ext-link-type="uri" xlink:href="https://www.equalityhumanrights.com/en/gypsies-and-travellers-simple-solutions-living-together">https://www.equalityhumanrights.com/en/gypsies-and-travellers-simple-solutions-living-together</ext-link><date-in-citation iso-8601-date="2022-04-13">April 13, 2022</date-in-citation></element-citation></ref><ref id="bib37"><element-citation publication-type="report"><person-group person-group-type="author"><collab>European Centre for Disease Prevention and Control</collab></person-group><year iso-8601-date="2016">2016</year><source>Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA</source><publisher-name>Stockholm</publisher-name></element-citation></ref><ref id="bib38"><element-citation publication-type="web"><person-group person-group-type="author"><collab>European Centre for Disease Prevention and Control</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA</article-title><ext-link ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/en/publications-data/public-health-guidance-screening-and-vaccination-infectious-diseases-newly">https://www.ecdc.europa.eu/en/publications-data/public-health-guidance-screening-and-vaccination-infectious-diseases-newly</ext-link><date-in-citation iso-8601-date="2022-11-18">November 18, 2022</date-in-citation></element-citation></ref><ref id="bib39"><element-citation publication-type="web"><person-group person-group-type="author"><collab>European Centre for Disease Prevention and Control</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Hepatitis B and C testing in the EU/EEA: progress in reaching the elimination targets</article-title><ext-link ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/en/publications-data/hepatitis-b-and-c-testing-eueea-progress-reaching-elimination-targets">https://www.ecdc.europa.eu/en/publications-data/hepatitis-b-and-c-testing-eueea-progress-reaching-elimination-targets</ext-link><date-in-citation iso-8601-date="2022-11-18">November 18, 2022</date-in-citation></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evlampidou</surname><given-names>I</given-names></name><name><surname>Hickman</surname><given-names>M</given-names></name><name><surname>Irish</surname><given-names>C</given-names></name><name><surname>Young</surname><given-names>N</given-names></name><name><surname>Oliver</surname><given-names>I</given-names></name><name><surname>Gillett</surname><given-names>S</given-names></name><name><surname>Cochrane</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Low hepatitis B testing among migrants: a cross-sectional study in a UK city</article-title><source>The British Journal of General Practice</source><volume>66</volume><fpage>e382</fpage><lpage>e391</lpage><pub-id pub-id-type="doi">10.3399/bjgp16X684817</pub-id><pub-id pub-id-type="pmid">27025556</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Fair</surname><given-names>H</given-names></name><name><surname>Walmsley</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Prison Populations Continue To Rise In Many Parts Of The World, New Report Published By The Institute For Crime &amp; Justice Policy Research Shows</article-title><ext-link ext-link-type="uri" xlink:href="https://www.icpr.org.uk/news-events/2021/prison-populations-continue-rise-many-parts-world-new-report-published-institute#:~:text=According%20to%20published%20prison%20population,in%20North%20Korea%20are%20included">https://www.icpr.org.uk/news-events/2021/prison-populations-continue-rise-many-parts-world-new-report-published-institute#:~:text=According%20to%20published%20prison%20population,in%20North%20Korea%20are%20included</ext-link><date-in-citation iso-8601-date="2022-05-25">May 25, 2022</date-in-citation></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrant</surname><given-names>O</given-names></name><name><surname>Eisen</surname><given-names>S</given-names></name><name><surname>van Tulleken</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>A</given-names></name><name><surname>Longley</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Why asylum seekers deserve better healthcare, and how we can give it to them</article-title><source>BMJ</source><volume>376</volume><elocation-id>3069</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.n3069</pub-id><pub-id pub-id-type="pmid">34992052</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazel</surname><given-names>S</given-names></name><name><surname>Danesh</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Serious mental disorder in 23000 prisoners: a systematic review of 62 surveys</article-title><source>Lancet</source><volume>359</volume><fpage>545</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)07740-1</pub-id><pub-id pub-id-type="pmid">11867106</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeland</surname><given-names>C</given-names></name><name><surname>Racho</surname><given-names>R</given-names></name><name><surname>Kamischke</surname><given-names>M</given-names></name><name><surname>Moraras</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Kendrick</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Health-related quality of life for adults living with hepatitis B in the united states: a qualitative assessment</article-title><source>Journal of Patient-Reported Outcomes</source><volume>5</volume><elocation-id>121</elocation-id><pub-id pub-id-type="doi">10.1186/s41687-021-00398-8</pub-id><pub-id pub-id-type="pmid">34757456</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genberg</surname><given-names>BL</given-names></name><name><surname>Astemborski</surname><given-names>J</given-names></name><name><surname>Vlahov</surname><given-names>D</given-names></name><name><surname>Kirk</surname><given-names>GD</given-names></name><name><surname>Mehta</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Incarceration and injection drug use in baltimore, maryland</article-title><source>Addiction</source><volume>110</volume><fpage>1152</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1111/add.12938</pub-id><pub-id pub-id-type="pmid">25845621</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gitto</surname><given-names>S</given-names></name><name><surname>Micco</surname><given-names>L</given-names></name><name><surname>Conti</surname><given-names>F</given-names></name><name><surname>Andreone</surname><given-names>P</given-names></name><name><surname>Bernardi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Alcohol and viral hepatitis: a mini-review</article-title><source>Digestive and Liver Disease</source><volume>41</volume><fpage>67</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2008.05.009</pub-id><pub-id pub-id-type="pmid">18602355</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graber-Stiehl</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The silent epidemic killing more people than HIV, malaria or TB</article-title><source>Nature</source><volume>564</volume><fpage>24</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/d41586-018-07592-7</pub-id><pub-id pub-id-type="pmid">30518904</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>A</given-names></name><name><surname>Vedio</surname><given-names>A</given-names></name><name><surname>Stone</surname><given-names>B</given-names></name><name><surname>Green</surname><given-names>S</given-names></name><name><surname>Bronsdon</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Targeted testing in primary care demonstrates high prevalence of hepatitis B infection within the slovak-roma population in sheffield, UK</article-title><source>Journal of Viral Hepatitis</source><volume>21</volume><fpage>e138</fpage><lpage>e139</lpage><pub-id pub-id-type="doi">10.1111/jvh.12287</pub-id><pub-id pub-id-type="pmid">25056611</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harawa</surname><given-names>NT</given-names></name><name><surname>Sweat</surname><given-names>J</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Sylla</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sex and condom use in a large jail unit for men who have sex with men (MSM) and male-to-female transgenders</article-title><source>Journal of Health Care for the Poor and Underserved</source><volume>21</volume><fpage>1071</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1353/hpu.0.0349</pub-id><pub-id pub-id-type="pmid">20693745</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hla</surname><given-names>TK</given-names></name><name><surname>Bukulatjpi</surname><given-names>SM</given-names></name><name><surname>Binks</surname><given-names>P</given-names></name><name><surname>Gurruwiwi</surname><given-names>GG</given-names></name><name><surname>Dhurrkay</surname><given-names>RG</given-names></name><name><surname>Davies</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A “one stop liver shop” approach improves the cascade-of-care for aboriginal and torres strait islander australians living with chronic hepatitis B in the northern territory of australia: results of A novel care delivery model</article-title><source>International Journal for Equity in Health</source><volume>19</volume><elocation-id>64</elocation-id><pub-id pub-id-type="doi">10.1186/s12939-020-01180-w</pub-id><pub-id pub-id-type="pmid">32381081</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Holmstrom</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Understanding health needs of the Traveller community</article-title><ext-link ext-link-type="uri" xlink:href="https://www.rcplondon.ac.uk/news/understanding-health-needs-traveller-community">https://www.rcplondon.ac.uk/news/understanding-health-needs-traveller-community</ext-link><date-in-citation iso-8601-date="2022-04-13">April 13, 2022</date-in-citation></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howell</surname><given-names>J</given-names></name><name><surname>Pedrana</surname><given-names>A</given-names></name><name><surname>Cowie</surname><given-names>BC</given-names></name><name><surname>Doyle</surname><given-names>J</given-names></name><name><surname>Getahun</surname><given-names>A</given-names></name><name><surname>Ward</surname><given-names>J</given-names></name><name><surname>Gane</surname><given-names>E</given-names></name><name><surname>Cunningham</surname><given-names>C</given-names></name><name><surname>Wallace</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Malani</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name><name><surname>Hellard</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific islands and territories: where are we now and barriers to meeting World Health organization targets by 2030</article-title><source>Journal of Gastroenterology and Hepatology</source><volume>34</volume><fpage>40</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1111/jgh.14457</pub-id><pub-id pub-id-type="pmid">30151932</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutton</surname><given-names>DW</given-names></name><name><surname>Toy</surname><given-names>M</given-names></name><name><surname>Salomon</surname><given-names>JA</given-names></name><name><surname>Conners</surname><given-names>EE</given-names></name><name><surname>Nelson</surname><given-names>NP</given-names></name><name><surname>Harris</surname><given-names>AM</given-names></name><name><surname>So</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cost-Effectiveness of hepatitis B testing and vaccination of adults seeking care for sexually transmitted infections</article-title><source>Sexually Transmitted Diseases</source><volume>49</volume><fpage>517</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1097/OLQ.0000000000001632</pub-id><pub-id pub-id-type="pmid">35312661</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="report"><person-group person-group-type="author"><collab>International organisation for migration</collab></person-group><year iso-8601-date="2021">2021</year><source>World migration report 2022</source><publisher-name>World Migration Repeort Series</publisher-name></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeal</surname><given-names>N</given-names></name><name><surname>Salisbury</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Self-Reported experiences of health services among female street-based prostitutes: a cross-sectional survey</article-title><source>The British Journal of General Practice</source><volume>54</volume><fpage>515</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">15239913</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamarulzaman</surname><given-names>A</given-names></name><name><surname>Reid</surname><given-names>SE</given-names></name><name><surname>Schwitters</surname><given-names>A</given-names></name><name><surname>Wiessing</surname><given-names>L</given-names></name><name><surname>El-Bassel</surname><given-names>N</given-names></name><name><surname>Dolan</surname><given-names>K</given-names></name><name><surname>Moazen</surname><given-names>B</given-names></name><name><surname>Wirtz</surname><given-names>AL</given-names></name><name><surname>Verster</surname><given-names>A</given-names></name><name><surname>Altice</surname><given-names>FL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners</article-title><source>Lancet</source><volume>388</volume><fpage>1115</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)30769-3</pub-id><pub-id pub-id-type="pmid">27427456</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JU</given-names></name><name><surname>Ingiliz</surname><given-names>P</given-names></name><name><surname>Shimakawa</surname><given-names>Y</given-names></name><name><surname>Lemoine</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Improving care of migrants is key for viral hepatitis elimination in Europe</article-title><source>Bulletin of the World Health Organization</source><volume>99</volume><fpage>280</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.2471/BLT.20.260919</pub-id><pub-id pub-id-type="pmid">33953445</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kowo</surname><given-names>MP</given-names></name><name><surname>Andoulo</surname><given-names>FA</given-names></name><name><surname>Sizimboue</surname><given-names>DT</given-names></name><name><surname>Ndam</surname><given-names>AWN</given-names></name><name><surname>Ngek</surname><given-names>LT</given-names></name><name><surname>Kouanfack</surname><given-names>C</given-names></name><name><surname>Leundji</surname><given-names>H</given-names></name><name><surname>Djanteng</surname><given-names>R</given-names></name><name><surname>Ondo</surname><given-names>BE</given-names></name><name><surname>Torimiro</surname><given-names>JN</given-names></name><name><surname>Ndam</surname><given-names>ECN</given-names></name><name><surname>Njoya</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Seroprevalence of hepatitis B and associated factors among inmates: a cross sectional study in the douala new bell prison, cameroon</article-title><source>The Pan African Medical Journal</source><volume>38</volume><elocation-id>355</elocation-id><pub-id pub-id-type="doi">10.11604/pamj.2021.38.355.20386</pub-id><pub-id pub-id-type="pmid">34367434</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Torre</surname><given-names>G</given-names></name><name><surname>Miele</surname><given-names>L</given-names></name><name><surname>Chiaradia</surname><given-names>G</given-names></name><name><surname>Mannocci</surname><given-names>A</given-names></name><name><surname>Reali</surname><given-names>M</given-names></name><name><surname>Gasbarrini</surname><given-names>G</given-names></name><name><surname>De Vito</surname><given-names>E</given-names></name><name><surname>Grieco</surname><given-names>A</given-names></name><name><surname>Ricciardi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Socio-Demographic determinants of coinfections by HIV, hepatitis B and hepatitis C viruses in central Italian prisoners</article-title><source>BMC Infectious Diseases</source><volume>7</volume><elocation-id>100</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2334-7-100</pub-id><pub-id pub-id-type="pmid">17760979</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Leeds gate</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Leeds Gypsy &amp; Traveller Exchange</article-title><ext-link ext-link-type="uri" xlink:href="https://www.leedsgate.co.uk/about-us">https://www.leedsgate.co.uk/about-us</ext-link><date-in-citation iso-8601-date="2022-04-13">April 13, 2022</date-in-citation></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemoine</surname><given-names>M</given-names></name><name><surname>Eholié</surname><given-names>S</given-names></name><name><surname>Lacombe</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach</article-title><source>Journal of Hepatology</source><volume>62</volume><fpage>469</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2014.10.008</pub-id><pub-id pub-id-type="pmid">25457207</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leuridan</surname><given-names>E</given-names></name><name><surname>Wouters</surname><given-names>K</given-names></name><name><surname>Stalpaert</surname><given-names>M</given-names></name><name><surname>Van Damme</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Male sex workers in Antwerp, Belgium: a descriptive study</article-title><source>International Journal of STD &amp; AIDS</source><volume>16</volume><fpage>744</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1258/095646205774763072</pub-id><pub-id pub-id-type="pmid">16303070</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z-M</given-names></name><name><surname>Kong</surname><given-names>C-Y</given-names></name><name><surname>Zhang</surname><given-names>S-L</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Z-Y</given-names></name><name><surname>Wang</surname><given-names>L-S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Alcohol and HBV synergistically promote hepatic steatosis</article-title><source>Annals of Hepatology</source><volume>18</volume><fpage>913</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1016/j.aohep.2019.04.013</pub-id><pub-id pub-id-type="pmid">31147179</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luchenski</surname><given-names>S</given-names></name><name><surname>Maguire</surname><given-names>N</given-names></name><name><surname>Aldridge</surname><given-names>RW</given-names></name><name><surname>Hayward</surname><given-names>A</given-names></name><name><surname>Story</surname><given-names>A</given-names></name><name><surname>Perri</surname><given-names>P</given-names></name><name><surname>Withers</surname><given-names>J</given-names></name><name><surname>Clint</surname><given-names>S</given-names></name><name><surname>Fitzpatrick</surname><given-names>S</given-names></name><name><surname>Hewett</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>What works in inclusion health: overview of effective interventions for marginalised and excluded populations</article-title><source>Lancet</source><volume>391</volume><fpage>266</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31959-1</pub-id><pub-id pub-id-type="pmid">29137868</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ly</surname><given-names>TDA</given-names></name><name><surname>Castaneda</surname><given-names>S</given-names></name><name><surname>Hoang</surname><given-names>VT</given-names></name><name><surname>Dao</surname><given-names>TL</given-names></name><name><surname>Gautret</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Vaccine-preventable diseases other than tuberculosis, and homelessness: a scoping review of the published literature, 1980 to 2020</article-title><source>Vaccine</source><volume>39</volume><fpage>1205</fpage><lpage>1224</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.01.035</pub-id><pub-id pub-id-type="pmid">33509694</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ly</surname><given-names>TDA</given-names></name><name><surname>Hoang</surname><given-names>VT</given-names></name><name><surname>Louni</surname><given-names>M</given-names></name><name><surname>Dao</surname><given-names>TL</given-names></name><name><surname>Badiaga</surname><given-names>S</given-names></name><name><surname>Tissot-Dupont</surname><given-names>H</given-names></name><name><surname>Brouqui</surname><given-names>P</given-names></name><name><surname>Colson</surname><given-names>P</given-names></name><name><surname>Gautret</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Epidemiological serosurvey and molecular characterization of sexually transmitted infections among 1890 sheltered homeless people in marseille: cross-sectional one day-surveys (2000-2015)</article-title><source>The Journal of Infection</source><volume>82</volume><fpage>60</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.11.026</pub-id><pub-id pub-id-type="pmid">33279534</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macejova</surname><given-names>Z</given-names></name><name><surname>Kristian</surname><given-names>P</given-names></name><name><surname>Janicko</surname><given-names>M</given-names></name><name><surname>Halanova</surname><given-names>M</given-names></name><name><surname>Drazilova</surname><given-names>S</given-names></name><name><surname>Antolova</surname><given-names>D</given-names></name><name><surname>Marekova</surname><given-names>M</given-names></name><name><surname>Pella</surname><given-names>D</given-names></name><name><surname>Madarasova-Geckova</surname><given-names>A</given-names></name><name><surname>Jarcuska</surname><given-names>P</given-names></name><name><surname>Team</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The Roma population living in segregated settlements in eastern Slovakia has a higher prevalence of metabolic syndrome, kidney disease, viral hepatitis B and E, and some parasitic diseases compared to the majority population</article-title><source>International Journal of Environmental Research and Public Health</source><volume>17</volume><elocation-id>3112</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph17093112</pub-id><pub-id pub-id-type="pmid">32365672</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magri</surname><given-names>MC</given-names></name><name><surname>Nunes</surname><given-names>AK</given-names></name><name><surname>Dantas</surname><given-names>BP</given-names></name><name><surname>Manchiero</surname><given-names>C</given-names></name><name><surname>Prata</surname><given-names>TVG</given-names></name><name><surname>Alves</surname><given-names>GM</given-names></name><name><surname>Tengan</surname><given-names>FM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Meta-analysis of the prevalence of HBV infection among alcohol users worldwide</article-title><source>Alcohol and Alcoholism</source><volume>55</volume><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1093/alcalc/agz102</pub-id><pub-id pub-id-type="pmid">31912149</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mak</surname><given-names>R</given-names></name><name><surname>Traen</surname><given-names>A</given-names></name><name><surname>Claeyssens</surname><given-names>M</given-names></name><name><surname>Van Renterghem</surname><given-names>L</given-names></name><name><surname>Leroux-Roels</surname><given-names>G</given-names></name><name><surname>Van Damme</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Hepatitis B vaccination for sex workers: do outreach programmes perform better?</article-title><source>Sexually Transmitted Infections</source><volume>79</volume><fpage>157</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1136/sti.79.2.157</pub-id><pub-id pub-id-type="pmid">12690142</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maponga</surname><given-names>TG</given-names></name><name><surname>McNaughton</surname><given-names>AL</given-names></name><name><surname>van Schalkwyk</surname><given-names>M</given-names></name><name><surname>Hugo</surname><given-names>S</given-names></name><name><surname>Nwankwo</surname><given-names>C</given-names></name><name><surname>Taljaard</surname><given-names>J</given-names></name><name><surname>Mokaya</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>DA</given-names></name><name><surname>van Vuuren</surname><given-names>C</given-names></name><name><surname>Goedhals</surname><given-names>D</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Andersson</surname><given-names>MI</given-names></name><name><surname>Preiser</surname><given-names>W</given-names></name><name><surname>van Rensburg</surname><given-names>C</given-names></name><name><surname>Matthews</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort</article-title><source>The Journal of Infection</source><volume>81</volume><fpage>121</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.04.037</pub-id><pub-id pub-id-type="pmid">32360882</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matos</surname><given-names>MA</given-names></name><name><surname>França</surname><given-names>DD</given-names></name><name><surname>Carneiro</surname><given-names>M</given-names></name><name><surname>Martins</surname><given-names>RMB</given-names></name><name><surname>Kerr</surname><given-names>L</given-names></name><name><surname>Caetano</surname><given-names>KAA</given-names></name><name><surname>Pinheiro</surname><given-names>RS</given-names></name><name><surname>Araújo</surname><given-names>LA</given-names></name><name><surname>Mota</surname><given-names>RMS</given-names></name><name><surname>Matos</surname><given-names>MAD</given-names></name><name><surname>Motta-Castro</surname><given-names>ARC</given-names></name><name><surname>Teles</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Viral hepatitis in female sex workers using the respondent-driven sampling</article-title><source>Revista de Saude Publica</source><volume>51</volume><elocation-id>65</elocation-id><pub-id pub-id-type="doi">10.1590/S1518-8787.2017051006540</pub-id><pub-id pub-id-type="pmid">28678904</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>PC</given-names></name><name><surname>Jack</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Abbott</surname><given-names>J</given-names></name><name><surname>Bryce</surname><given-names>K</given-names></name><name><surname>Cheng</surname><given-names>B</given-names></name><name><surname>Ghosh</surname><given-names>I</given-names></name><name><surname>Story</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Munoz</surname><given-names>C</given-names></name><name><surname>Bell</surname><given-names>J</given-names></name><name><surname>Riddell</surname><given-names>S</given-names></name><name><surname>Goldring</surname><given-names>A</given-names></name><name><surname>Goddard</surname><given-names>C</given-names></name><name><surname>Moraras</surname><given-names>K</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Lazarus</surname><given-names>JV</given-names></name><name><surname>Elsharkawy</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>A call for advocacy and patient voice to eliminate hepatitis B virus infection</article-title><source>The Lancet. Gastroenterology &amp; Hepatology</source><volume>7</volume><fpage>282</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(21)00475-1</pub-id><pub-id pub-id-type="pmid">35278394</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>PC</given-names></name><name><surname>Maponga</surname><given-names>T</given-names></name><name><surname>Ghosh</surname><given-names>I</given-names></name><name><surname>Lemoine</surname><given-names>M</given-names></name><name><surname>Ocama</surname><given-names>P</given-names></name><name><surname>Abubakar</surname><given-names>I</given-names></name><name><surname>Story</surname><given-names>A</given-names></name><name><surname>Flanagan</surname><given-names>S</given-names></name><name><surname>Ochodo</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Hepatitis B virus: infection, liver disease, carcinogen or syndemic threat? remodelling the clinical and public health response</article-title><source>PLOS Global Public Health</source><volume>2</volume><elocation-id>e0001359</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgph.0001359</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzitelli</surname><given-names>M</given-names></name><name><surname>Greco</surname><given-names>G</given-names></name><name><surname>Serapide</surname><given-names>F</given-names></name><name><surname>Scaglione</surname><given-names>V</given-names></name><name><surname>Morrone</surname><given-names>H</given-names></name><name><surname>Marascio</surname><given-names>N</given-names></name><name><surname>Giancotti</surname><given-names>A</given-names></name><name><surname>Liberto</surname><given-names>M</given-names></name><name><surname>Matera</surname><given-names>G</given-names></name><name><surname>Trecarichi</surname><given-names>E</given-names></name><name><surname>Torti</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Outcome of HBV screening and vaccination in a migrant population in southern Italy</article-title><source>Le Infezioni in Medicina</source><volume>29</volume><fpage>236</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">34061789</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mc Grath-Lone</surname><given-names>L</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>Hughes</surname><given-names>G</given-names></name><name><surname>Ward</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The sexual health of female sex workers compared with other women in England: analysis of cross-sectional data from genitourinary medicine clinics</article-title><source>Sexually Transmitted Infections</source><volume>90</volume><fpage>344</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1136/sextrans-2013-051381</pub-id><pub-id pub-id-type="pmid">24493858</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFadden</surname><given-names>A</given-names></name><name><surname>Siebelt</surname><given-names>L</given-names></name><name><surname>Gavine</surname><given-names>A</given-names></name><name><surname>Atkin</surname><given-names>K</given-names></name><name><surname>Bell</surname><given-names>K</given-names></name><name><surname>Innes</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>H</given-names></name><name><surname>Jackson</surname><given-names>C</given-names></name><name><surname>Haggi</surname><given-names>H</given-names></name><name><surname>MacGillivray</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Gypsy, Roma and traveller access to and engagement with health services: a systematic review</article-title><source>European Journal of Public Health</source><volume>28</volume><fpage>74</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1093/eurpub/ckx226</pub-id><pub-id pub-id-type="pmid">29346666</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNaughton</surname><given-names>AL</given-names></name><name><surname>Lourenço</surname><given-names>J</given-names></name><name><surname>Hattingh</surname><given-names>L</given-names></name><name><surname>Adland</surname><given-names>E</given-names></name><name><surname>Daniels</surname><given-names>S</given-names></name><name><surname>Van Zyl</surname><given-names>A</given-names></name><name><surname>Akiror</surname><given-names>CS</given-names></name><name><surname>Wareing</surname><given-names>S</given-names></name><name><surname>Jeffery</surname><given-names>K</given-names></name><name><surname>Ansari</surname><given-names>MA</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Goulder</surname><given-names>PJR</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Jooste</surname><given-names>P</given-names></name><name><surname>Matthews</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hbv vaccination and PMTCT as elimination tools in the presence of HIV: insights from a clinical cohort and dynamic model</article-title><source>BMC Medicine</source><volume>17</volume><elocation-id>43</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-019-1269-x</pub-id><pub-id pub-id-type="pmid">30786896</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNaughton</surname><given-names>AL</given-names></name><name><surname>Lemoine</surname><given-names>M</given-names></name><name><surname>van Rensburg</surname><given-names>C</given-names></name><name><surname>Matthews</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Extending treatment eligibility for chronic hepatitis B virus infection</article-title><source>Nature Reviews. Gastroenterology &amp; Hepatology</source><volume>18</volume><fpage>146</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1038/s41575-020-00398-x</pub-id><pub-id pub-id-type="pmid">33323992</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendenhall</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Syndemics: a new path for global health research</article-title><source>Lancet</source><volume>389</volume><fpage>889</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)30602-5</pub-id><pub-id pub-id-type="pmid">28271827</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>NTGP</given-names></name><name><surname>de Souza</surname><given-names>RL</given-names></name><name><surname>Monteiro</surname><given-names>JC</given-names></name><name><surname>Costa</surname><given-names>IB</given-names></name><name><surname>Siravenha</surname><given-names>LQ</given-names></name><name><surname>da Luz</surname><given-names>ALB</given-names></name><name><surname>de Almeida</surname><given-names>NCC</given-names></name><name><surname>Oliveira-Filho</surname><given-names>AB</given-names></name><name><surname>Laurentino</surname><given-names>RV</given-names></name><name><surname>Machado</surname><given-names>LFA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Seroprevalence of HBV and HCV in female sex workers from four cities in the state of pará, Northern Brazil</article-title><source>Journal of Medical Virology</source><volume>93</volume><fpage>3730</fpage><lpage>3737</lpage><pub-id pub-id-type="doi">10.1002/jmv.26759</pub-id><pub-id pub-id-type="pmid">33368401</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moazen</surname><given-names>B</given-names></name><name><surname>Saeedi Moghaddam</surname><given-names>S</given-names></name><name><surname>Silbernagl</surname><given-names>MA</given-names></name><name><surname>Lotfizadeh</surname><given-names>M</given-names></name><name><surname>Bosworth</surname><given-names>RJ</given-names></name><name><surname>Alammehrjerdi</surname><given-names>Z</given-names></name><name><surname>Kinner</surname><given-names>SA</given-names></name><name><surname>Wirtz</surname><given-names>AL</given-names></name><name><surname>Bärnighausen</surname><given-names>TW</given-names></name><name><surname>Stöver</surname><given-names>HJ</given-names></name><name><surname>Dolan</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Prevalence of drug injection, sexual activity, tattooing, and piercing among prison inmates</article-title><source>Epidemiologic Reviews</source><volume>40</volume><fpage>58</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1093/epirev/mxy002</pub-id><pub-id pub-id-type="pmid">29860343</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Mofokeng</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Barriers to recruitment of adults with HBV for participation in clinical research studies</article-title><conf-name>Conference on Liver Disease in Africa. Virtual</conf-name></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motavalli</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>JL</given-names></name><name><surname>Childs</surname><given-names>E</given-names></name><name><surname>Valente</surname><given-names>PK</given-names></name><name><surname>Salhaney</surname><given-names>P</given-names></name><name><surname>Olson</surname><given-names>J</given-names></name><name><surname>Biancarelli</surname><given-names>DL</given-names></name><name><surname>Edeza</surname><given-names>A</given-names></name><name><surname>Earlywine</surname><given-names>JJ</given-names></name><name><surname>Marshall</surname><given-names>BDL</given-names></name><name><surname>Drainoni</surname><given-names>M-L</given-names></name><name><surname>Mimiaga</surname><given-names>MJ</given-names></name><name><surname>Biello</surname><given-names>KB</given-names></name><name><surname>Bazzi</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>“Health is on the back burner:” multilevel barriers and facilitators to primary care among people who inject drugs</article-title><source>Journal of General Internal Medicine</source><volume>36</volume><fpage>129</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1007/s11606-020-06201-6</pub-id><pub-id pub-id-type="pmid">32918199</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakitanda</surname><given-names>AO</given-names></name><name><surname>Montanari</surname><given-names>L</given-names></name><name><surname>Tavoschi</surname><given-names>L</given-names></name><name><surname>Mozalevskis</surname><given-names>A</given-names></name><name><surname>Duffell</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hepatitis B virus infection in EU/EEA and united kingdom prisons: a descriptive analysis</article-title><source>Epidemiology and Infection</source><volume>149</volume><elocation-id>e59</elocation-id><pub-id pub-id-type="doi">10.1017/S0950268821000169</pub-id><pub-id pub-id-type="pmid">33487201</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="web"><person-group person-group-type="author"><collab>National institutes of health</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Estimates of Funding for Various Research, Condition, and Disease Categories</article-title><ext-link ext-link-type="uri" xlink:href="https://report.nih.gov/funding/categorical-spending">https://report.nih.gov/funding/categorical-spending</ext-link><date-in-citation iso-8601-date="2022-11-24">November 24, 2022</date-in-citation></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nayagam</surname><given-names>S</given-names></name><name><surname>Conteh</surname><given-names>L</given-names></name><name><surname>Sicuri</surname><given-names>E</given-names></name><name><surname>Shimakawa</surname><given-names>Y</given-names></name><name><surname>Suso</surname><given-names>P</given-names></name><name><surname>Tamba</surname><given-names>S</given-names></name><name><surname>Njie</surname><given-names>R</given-names></name><name><surname>Njai</surname><given-names>H</given-names></name><name><surname>Lemoine</surname><given-names>M</given-names></name><name><surname>Hallett</surname><given-names>TB</given-names></name><name><surname>Thursz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in the gambia: an economic modelling analysis</article-title><source>The Lancet. Global Health</source><volume>4</volume><fpage>e568</fpage><lpage>e578</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(16)30101-2</pub-id><pub-id pub-id-type="pmid">27443782</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nebbia</surname><given-names>G</given-names></name><name><surname>Ruf</surname><given-names>M</given-names></name><name><surname>Hunter</surname><given-names>L</given-names></name><name><surname>Balasegaram</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>T</given-names></name><name><surname>Kulasegaram</surname><given-names>R</given-names></name><name><surname>Surey</surname><given-names>J</given-names></name><name><surname>Khan</surname><given-names>Z</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Karo</surname><given-names>B</given-names></name><name><surname>Snell</surname><given-names>L</given-names></name><name><surname>Flower</surname><given-names>B</given-names></name><name><surname>Evans</surname><given-names>H</given-names></name><name><surname>Douthwaite</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>VirA+EmiC project: evaluating real-world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department</article-title><source>Journal of Viral Hepatitis</source><volume>29</volume><fpage>559</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1111/jvh.13676</pub-id><pub-id pub-id-type="pmid">35357750</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Carroll</surname><given-names>A</given-names></name><name><surname>Irving</surname><given-names>N</given-names></name><name><surname>O’Neill</surname><given-names>J</given-names></name><name><surname>Flanagan</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A review of a GP registrar-run mobile health clinic for homeless people</article-title><source>Irish Journal of Medical Science</source><volume>186</volume><fpage>541</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1007/s11845-016-1527-2</pub-id><pub-id pub-id-type="pmid">27882501</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Øgård-Repål</surname><given-names>A</given-names></name><name><surname>Berg</surname><given-names>RC</given-names></name><name><surname>Fossum</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Peer support for people living with HIV: A scoping review</article-title><source>Health Promotion Practice</source><volume>24</volume><fpage>172</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1177/15248399211049824</pub-id><pub-id pub-id-type="pmid">34693785</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Hara</surname><given-names>GA</given-names></name><name><surname>McNaughton</surname><given-names>AL</given-names></name><name><surname>Maponga</surname><given-names>T</given-names></name><name><surname>Jooste</surname><given-names>P</given-names></name><name><surname>Ocama</surname><given-names>P</given-names></name><name><surname>Chilengi</surname><given-names>R</given-names></name><name><surname>Mokaya</surname><given-names>J</given-names></name><name><surname>Liyayi</surname><given-names>MI</given-names></name><name><surname>Wachira</surname><given-names>T</given-names></name><name><surname>Gikungi</surname><given-names>DM</given-names></name><name><surname>Burbridge</surname><given-names>L</given-names></name><name><surname>O’Donnell</surname><given-names>D</given-names></name><name><surname>Akiror</surname><given-names>CS</given-names></name><name><surname>Sloan</surname><given-names>D</given-names></name><name><surname>Torimiro</surname><given-names>J</given-names></name><name><surname>Yindom</surname><given-names>LM</given-names></name><name><surname>Walton</surname><given-names>R</given-names></name><name><surname>Andersson</surname><given-names>M</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>Newton</surname><given-names>R</given-names></name><name><surname>Matthews</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hepatitis B virus infection as a neglected tropical disease</article-title><source>PLOS Neglected Tropical Diseases</source><volume>11</volume><elocation-id>e0005842</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0005842</pub-id><pub-id pub-id-type="pmid">28981505</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Keefe</surname><given-names>D</given-names></name><name><surname>Stoové</surname><given-names>M</given-names></name><name><surname>Doyle</surname><given-names>J</given-names></name><name><surname>Dietze</surname><given-names>P</given-names></name><name><surname>Hellard</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Injecting drug use in low and middle-income countries: opportunities to improve care and prevent harm</article-title><source>Journal of Viral Hepatitis</source><volume>24</volume><fpage>714</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1111/jvh.12741</pub-id><pub-id pub-id-type="pmid">28632952</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osiowy</surname><given-names>C</given-names></name><name><surname>Simons</surname><given-names>BC</given-names></name><name><surname>Rempel</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Distribution of viral hepatitis in Indigenous populations of North America and the Circumpolar Arctic</article-title><source>Antiviral Therapy</source><volume>18</volume><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.3851/IMP2597</pub-id><pub-id pub-id-type="pmid">23792414</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paisi</surname><given-names>M</given-names></name><name><surname>Crombag</surname><given-names>N</given-names></name><name><surname>Burns</surname><given-names>L</given-names></name><name><surname>Bogaerts</surname><given-names>A</given-names></name><name><surname>Withers</surname><given-names>L</given-names></name><name><surname>Bates</surname><given-names>L</given-names></name><name><surname>Crowley</surname><given-names>D</given-names></name><name><surname>Witton</surname><given-names>R</given-names></name><name><surname>Shawe</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: a mixed-methods systematic review</article-title><source>Health Expectations</source><volume>25</volume><fpage>48</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1111/hex.13400</pub-id><pub-id pub-id-type="pmid">34862710</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmateer</surname><given-names>NE</given-names></name><name><surname>Goldberg</surname><given-names>DJ</given-names></name><name><surname>Munro</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Yeung</surname><given-names>A</given-names></name><name><surname>Wallace</surname><given-names>LA</given-names></name><name><surname>Mitchell</surname><given-names>A</given-names></name><name><surname>Shepherd</surname><given-names>SJ</given-names></name><name><surname>Gunson</surname><given-names>RN</given-names></name><name><surname>Aitken</surname><given-names>C</given-names></name><name><surname>Hutchinson</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Association between universal hepatitis B prison vaccination, vaccine uptake and hepatitis B infection among people who inject drugs</article-title><source>Addiction</source><volume>113</volume><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1111/add.13944</pub-id><pub-id pub-id-type="pmid">28710874</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picchio</surname><given-names>CA</given-names></name><name><surname>Nomah</surname><given-names>DK</given-names></name><name><surname>Araujo</surname><given-names>SG</given-names></name><name><surname>Rando-Segura</surname><given-names>A</given-names></name><name><surname>Fernández</surname><given-names>E</given-names></name><name><surname>Buti</surname><given-names>M</given-names></name><name><surname>Rodríguez-Tajes</surname><given-names>S</given-names></name><name><surname>Lens</surname><given-names>S</given-names></name><name><surname>Rodríguez-Frías</surname><given-names>F</given-names></name><name><surname>Lazarus</surname><given-names>JV</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A novel model of care for simplified testing of HBV in african communities during the COVID-19 pandemic in spain</article-title><source>Scientific Reports</source><volume>11</volume><elocation-id>17063</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-96350-3</pub-id><pub-id pub-id-type="pmid">34433852</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plackett</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Why hepatitis B hits Aboriginal Australians especially hard</article-title><source>Nature</source><volume>603</volume><fpage>S62</fpage><lpage>S63</lpage><pub-id pub-id-type="doi">10.1038/d41586-022-00820-1</pub-id><pub-id pub-id-type="pmid">35354991</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pley</surname><given-names>CM</given-names></name><name><surname>McNaughton</surname><given-names>AL</given-names></name><name><surname>Matthews</surname><given-names>PC</given-names></name><name><surname>Lourenço</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The global impact of the COVID-19 pandemic on the prevention, diagnosis and treatment of hepatitis B virus (HBV) infection</article-title><source>BMJ Global Health</source><volume>6</volume><elocation-id>e004275</elocation-id><pub-id pub-id-type="doi">10.1136/bmjgh-2020-004275</pub-id><pub-id pub-id-type="pmid">33402334</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prestileo</surname><given-names>T</given-names></name><name><surname>Di Marco</surname><given-names>V</given-names></name><name><surname>Dino</surname><given-names>O</given-names></name><name><surname>Sanfilippo</surname><given-names>A</given-names></name><name><surname>Tutone</surname><given-names>M</given-names></name><name><surname>Milesi</surname><given-names>M</given-names></name><name><surname>Di Marco</surname><given-names>L</given-names></name><name><surname>Picchio</surname><given-names>CA</given-names></name><name><surname>Craxì</surname><given-names>A</given-names></name><name><surname>Lazarus</surname><given-names>JV</given-names></name><collab>Immigrant Take Care Advocacy team</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Effectiveness of a screening program for HBV, HCV, and HIV infections in african migrants to sicily</article-title><source>Digestive and Liver Disease</source><volume>54</volume><fpage>800</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2021.08.024</pub-id><pub-id pub-id-type="pmid">34649829</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qama</surname><given-names>A</given-names></name><name><surname>Allard</surname><given-names>N</given-names></name><name><surname>Cowie</surname><given-names>B</given-names></name><name><surname>Davis</surname><given-names>JS</given-names></name><name><surname>Davies</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hepatitis B in the Northern Territory: insights into the changing epidemiology of an ancient condition</article-title><source>Internal Medicine Journal</source><volume>51</volume><fpage>910</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1111/imj.15069</pub-id><pub-id pub-id-type="pmid">32975893</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashti</surname><given-names>R</given-names></name><name><surname>Sharafi</surname><given-names>H</given-names></name><name><surname>Alavian</surname><given-names>SM</given-names></name><name><surname>Moradi</surname><given-names>Y</given-names></name><name><surname>Mohamadi Bolbanabad</surname><given-names>A</given-names></name><name><surname>Moradi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Systematic review and meta-analysis of global prevalence of hbsag and HIV and HCV antibodies among people who inject drugs and female sex workers</article-title><source>Pathogens</source><volume>9</volume><elocation-id>432</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens9060432</pub-id><pub-id pub-id-type="pmid">32486342</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robotin</surname><given-names>MC</given-names></name><name><surname>George</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Community-Based hepatitis B screening: what works?</article-title><source>Hepatology International</source><volume>8</volume><fpage>478</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1007/s12072-014-9562-4</pub-id><pub-id pub-id-type="pmid">25298848</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robotin</surname><given-names>MC</given-names></name><name><surname>Wallace</surname><given-names>J</given-names></name><name><surname>Gallego</surname><given-names>G</given-names></name><name><surname>George</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hepatitis B and liver cancer: community awareness, knowledge and beliefs of middle eastern migrants in sydney, australia</article-title><source>International Journal of Environmental Research and Public Health</source><volume>18</volume><elocation-id>8534</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph18168534</pub-id><pub-id pub-id-type="pmid">34444285</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Royal College of Physicians</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Inclusion health: Designing services</article-title><ext-link ext-link-type="uri" xlink:href="https://www.rcpmedicalcare.org.uk/designing-services/themes/inclusion-health">https://www.rcpmedicalcare.org.uk/designing-services/themes/inclusion-health</ext-link><date-in-citation iso-8601-date="2022-05-18">May 18, 2022</date-in-citation></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>NK</given-names></name><name><surname>Nazar</surname><given-names>K</given-names></name><name><surname>Del Pino</surname><given-names>S</given-names></name><name><surname>Alonso Gonzalez</surname><given-names>M</given-names></name><name><surname>Díaz Bermúdez</surname><given-names>XP</given-names></name><name><surname>Ravasi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HIV, syphilis, and viral hepatitis among latin american indigenous peoples and afro-descendants: a systematic review</article-title><source>Revista Panamericana de Salud Publica = Pan American Journal of Public Health</source><volume>43</volume><elocation-id>e17</elocation-id><pub-id pub-id-type="doi">10.26633/RPSP.2019.17</pub-id><pub-id pub-id-type="pmid">31093241</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheibe</surname><given-names>A</given-names></name><name><surname>Young</surname><given-names>K</given-names></name><name><surname>Versfeld</surname><given-names>A</given-names></name><name><surname>Spearman</surname><given-names>CW</given-names></name><name><surname>Sonderup</surname><given-names>MW</given-names></name><name><surname>Prabdial-Sing</surname><given-names>N</given-names></name><name><surname>Puren</surname><given-names>A</given-names></name><name><surname>Hausler</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in south africa: findings from a seven-city cross-sectional survey (2017)</article-title><source>BMC Infectious Diseases</source><volume>20</volume><elocation-id>655</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-020-05359-y</pub-id><pub-id pub-id-type="pmid">32894072</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuelter-Trevisol</surname><given-names>F</given-names></name><name><surname>Custódio</surname><given-names>G</given-names></name><name><surname>Silva</surname><given-names>ACB</given-names></name><name><surname>Oliveira</surname><given-names>MB</given-names></name><name><surname>Wolfart</surname><given-names>A</given-names></name><name><surname>Trevisol</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hiv, hepatitis B and C, and syphilis prevalence and coinfection among sex workers in southern brazil</article-title><source>Revista Da Sociedade Brasileira de Medicina Tropical</source><volume>46</volume><fpage>493</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1590/0037-8682-1364-2013</pub-id><pub-id pub-id-type="pmid">23681430</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seedat</surname><given-names>F</given-names></name><name><surname>Hargreaves</surname><given-names>S</given-names></name><name><surname>Nellums</surname><given-names>LB</given-names></name><name><surname>Ouyang</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Friedland</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review</article-title><source>The Lancet. Infectious Diseases</source><volume>18</volume><fpage>e259</fpage><lpage>e271</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30117-8</pub-id><pub-id pub-id-type="pmid">29778396</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Shepherd-Banigan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><source>VA evidence-based synthesis program reports Primary Care Engagement Among Veterans with Experiences of Homelessness and Serious Mental Illness: An Evidence Map</source><publisher-name>Department of Veterans Affairs</publisher-name></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siersbaek</surname><given-names>R</given-names></name><name><surname>Ford</surname><given-names>JA</given-names></name><name><surname>Burke</surname><given-names>S</given-names></name><name><surname>Ní Cheallaigh</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Contexts and mechanisms that promote access to healthcare for populations experiencing homelessness: a realist review</article-title><source>BMJ Open</source><volume>11</volume><elocation-id>e043091</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2020-043091</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Story</surname><given-names>A</given-names></name><name><surname>Garber</surname><given-names>E</given-names></name><name><surname>Aldridge</surname><given-names>RW</given-names></name><name><surname>Smith</surname><given-names>CM</given-names></name><name><surname>Hall</surname><given-names>J</given-names></name><name><surname>Ferenando</surname><given-names>G</given-names></name><name><surname>Possas</surname><given-names>L</given-names></name><name><surname>Hemming</surname><given-names>S</given-names></name><name><surname>Wurie</surname><given-names>F</given-names></name><name><surname>Luchenski</surname><given-names>S</given-names></name><name><surname>Abubakar</surname><given-names>I</given-names></name><name><surname>McHugh</surname><given-names>TD</given-names></name><name><surname>White</surname><given-names>PJ</given-names></name><name><surname>Watson</surname><given-names>JM</given-names></name><name><surname>Lipman</surname><given-names>M</given-names></name><name><surname>Garfein</surname><given-names>R</given-names></name><name><surname>Hayward</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Management and control of tuberculosis control in socially complex groups: a research programme including three rcts</article-title><source>Programme Grants for Applied Research</source><volume>8</volume><fpage>1</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.3310/pgfar08090</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>WC</given-names></name><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>DD</given-names></name><name><surname>Ong</surname><given-names>JJ</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Ji</surname><given-names>F</given-names></name><name><surname>Yuen</surname><given-names>M-F</given-names></name><name><surname>Zhuang</surname><given-names>G</given-names></name><name><surname>Seto</surname><given-names>W-K</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cost-Effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation</article-title><source>The Lancet. Global Health</source><volume>10</volume><fpage>e278</fpage><lpage>e287</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(21)00517-9</pub-id><pub-id pub-id-type="pmid">35063115</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surey</surname><given-names>J</given-names></name><name><surname>Menezes</surname><given-names>D</given-names></name><name><surname>Francis</surname><given-names>M</given-names></name><name><surname>Gibbons</surname><given-names>J</given-names></name><name><surname>Sultan</surname><given-names>B</given-names></name><name><surname>Miah</surname><given-names>A</given-names></name><name><surname>Abubakar</surname><given-names>I</given-names></name><name><surname>Story</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>From peer-based to peer-led: redefining the role of peers across the hepatitis C care pathway: hepcare Europe</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>74</volume><fpage>v17</fpage><lpage>v23</lpage><pub-id pub-id-type="doi">10.1093/jac/dkz452</pub-id><pub-id pub-id-type="pmid">31782500</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surey</surname><given-names>J</given-names></name><name><surname>Francis</surname><given-names>M</given-names></name><name><surname>Gibbons</surname><given-names>J</given-names></name><name><surname>Leonard</surname><given-names>M</given-names></name><name><surname>Abubakar</surname><given-names>I</given-names></name><name><surname>Story</surname><given-names>A</given-names></name><name><surname>MacLellan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Practising critical resilience as an advanced peer support worker in london: a qualitative evaluation of a peer-led hepatitis C intervention amongst people experiencing homelessness who inject drugs</article-title><source>The International Journal on Drug Policy</source><volume>91</volume><elocation-id>103089</elocation-id><pub-id pub-id-type="doi">10.1016/j.drugpo.2020.103089</pub-id><pub-id pub-id-type="pmid">33460981</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tasa</surname><given-names>J</given-names></name><name><surname>Holmberg</surname><given-names>V</given-names></name><name><surname>Sainio</surname><given-names>S</given-names></name><name><surname>Kankkunen</surname><given-names>P</given-names></name><name><surname>Vehviläinen-Julkunen</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Maternal health care utilization and the obstetric outcomes of undocumented women in finland - a retrospective register-based study</article-title><source>BMC Pregnancy and Childbirth</source><volume>21</volume><elocation-id>191</elocation-id><pub-id pub-id-type="doi">10.1186/s12884-021-03642-7</pub-id><pub-id pub-id-type="pmid">33676438</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>JEB</given-names></name><name><surname>Surey</surname><given-names>J</given-names></name><name><surname>MacLellan</surname><given-names>J</given-names></name><name><surname>Francis</surname><given-names>M</given-names></name><name><surname>Abubakar</surname><given-names>I</given-names></name><name><surname>Stagg</surname><given-names>HR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hepatitis B vaccination uptake in hard-to-reach populations in london: a cross-sectional study</article-title><source>BMC Infectious Diseases</source><volume>19</volume><elocation-id>372</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-019-3926-2</pub-id><pub-id pub-id-type="pmid">31046683</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todd</surname><given-names>CS</given-names></name><name><surname>Nasir</surname><given-names>A</given-names></name><name><surname>Stanekzai</surname><given-names>MR</given-names></name><name><surname>Bautista</surname><given-names>CT</given-names></name><name><surname>Botros</surname><given-names>BA</given-names></name><name><surname>Scott</surname><given-names>PT</given-names></name><name><surname>Strathdee</surname><given-names>SA</given-names></name><name><surname>Tjaden</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Hiv, hepatitis B, and hepatitis C prevalence and associated risk behaviors among female sex workers in three afghan cities</article-title><source>AIDS</source><volume>24 Suppl 2</volume><fpage>S69</fpage><lpage>S75</lpage><pub-id pub-id-type="doi">10.1097/01.aids.0000386736.25296.8d</pub-id><pub-id pub-id-type="pmid">20610952</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tordrup</surname><given-names>D</given-names></name><name><surname>Hutin</surname><given-names>Y</given-names></name><name><surname>Stenberg</surname><given-names>K</given-names></name><name><surname>Lauer</surname><given-names>JA</given-names></name><name><surname>Hutton</surname><given-names>DW</given-names></name><name><surname>Toy</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>N</given-names></name><name><surname>Chhatwal</surname><given-names>J</given-names></name><name><surname>Ball</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cost-Effectiveness of testing and treatment for hepatitis B virus and hepatitis C virus infections: an analysis by scenarios, regions, and income</article-title><source>Value in Health</source><volume>23</volume><fpage>1552</fpage><lpage>1560</lpage><pub-id pub-id-type="doi">10.1016/j.jval.2020.06.015</pub-id><pub-id pub-id-type="pmid">33248510</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toy</surname><given-names>M</given-names></name><name><surname>Hutton</surname><given-names>D</given-names></name><name><surname>Harris</surname><given-names>AM</given-names></name><name><surname>Nelson</surname><given-names>N</given-names></name><name><surname>Salomon</surname><given-names>JA</given-names></name><name><surname>So</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cost-Effectiveness of 1-time universal screening for chronic hepatitis B infection in adults in the United States</article-title><source>Clinical Infectious Diseases</source><volume>74</volume><fpage>210</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab405</pub-id><pub-id pub-id-type="pmid">33956937</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tweed</surname><given-names>EJ</given-names></name><name><surname>Thomson</surname><given-names>RM</given-names></name><name><surname>Lewer</surname><given-names>D</given-names></name><name><surname>Sumpter</surname><given-names>C</given-names></name><name><surname>Kirolos</surname><given-names>A</given-names></name><name><surname>Southworth</surname><given-names>PM</given-names></name><name><surname>Purba</surname><given-names>AK</given-names></name><name><surname>Aldridge</surname><given-names>RW</given-names></name><name><surname>Hayward</surname><given-names>A</given-names></name><name><surname>Story</surname><given-names>A</given-names></name><name><surname>Hwang</surname><given-names>SW</given-names></name><name><surname>Katikireddi</surname><given-names>SV</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Health of people experiencing co-occurring homelessness, imprisonment, substance use, sex work and/or severe mental illness in high-income countries: a systematic review and meta-analysis</article-title><source>Journal of Epidemiology and Community Health</source><volume>75</volume><fpage>1010</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1136/jech-2020-215975</pub-id><pub-id pub-id-type="pmid">33893182</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="report"><person-group person-group-type="author"><collab>United Way Mumbai</collab></person-group><year iso-8601-date="2017">2017</year><source>Knowledge, attitude and practices of commercial sex workers towards hepatitis B: understanding the gaps</source><publisher-name>Webversion Impact Report</publisher-name></element-citation></ref><ref id="bib121"><element-citation publication-type="web"><person-group person-group-type="author"><collab>University College London Hospitals NHS Foundation Trust</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Find &amp; Treat Service</article-title><ext-link ext-link-type="uri" xlink:href="https://www.uclh.nhs.uk/our-services/find-service/tropical-and-infectious-diseases/find-treat-service">https://www.uclh.nhs.uk/our-services/find-service/tropical-and-infectious-diseases/find-treat-service</ext-link><date-in-citation iso-8601-date="2022-06-01">June 1, 2022</date-in-citation></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veselíny</surname><given-names>E</given-names></name><name><surname>Janicko</surname><given-names>M</given-names></name><name><surname>Drazilová</surname><given-names>S</given-names></name><name><surname>Siegfried</surname><given-names>L</given-names></name><name><surname>Pastvová</surname><given-names>L</given-names></name><name><surname>Schréter</surname><given-names>I</given-names></name><name><surname>Kristian</surname><given-names>P</given-names></name><name><surname>Viág</surname><given-names>L</given-names></name><name><surname>Jarcuska</surname><given-names>P</given-names></name><name><surname>Valková</surname><given-names>I</given-names></name><name><surname>Cáriková</surname><given-names>K</given-names></name><name><surname>Senajová</surname><given-names>G</given-names></name><name><surname>Fedacko</surname><given-names>J</given-names></name><name><surname>Pella</surname><given-names>D</given-names></name><name><surname>Mareková</surname><given-names>M</given-names></name><name><surname>Gecková</surname><given-names>AM</given-names></name><name><surname>Jarcuska</surname><given-names>P</given-names></name><collab>HepaMeta Team</collab></person-group><year iso-8601-date="2014">2014</year><article-title>High hepatitis B and low hepatitis C prevalence in roma population in eastern slovakia</article-title><source>Central European Journal of Public Health</source><volume>22</volume><fpage>S51</fpage><lpage>S56</lpage><pub-id pub-id-type="doi">10.21101/cejph.a3902</pub-id><pub-id pub-id-type="pmid">24847615</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>J</given-names></name><name><surname>McNally</surname><given-names>S</given-names></name><name><surname>Richmond</surname><given-names>J</given-names></name><name><surname>Hajarizadeh</surname><given-names>B</given-names></name><name><surname>Pitts</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Managing chronic hepatitis B: a qualitative study exploring the perspectives of people living with chronic hepatitis B in australia</article-title><source>BMC Research Notes</source><volume>4</volume><elocation-id>45</elocation-id><pub-id pub-id-type="doi">10.1186/1756-0500-4-45</pub-id><pub-id pub-id-type="pmid">21371332</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>Z</given-names></name><name><surname>Campbell</surname><given-names>L</given-names></name><name><surname>Surey</surname><given-names>J</given-names></name><name><surname>Platts</surname><given-names>S</given-names></name><name><surname>Glass</surname><given-names>R</given-names></name><name><surname>Hickman</surname><given-names>M</given-names></name><name><surname>Story</surname><given-names>A</given-names></name><name><surname>Vickerman</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The cost-effectiveness of an HCV outreach intervention for at-risk populations in london, UK</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>74</volume><fpage>v5</fpage><lpage>v16</lpage><pub-id pub-id-type="doi">10.1093/jac/dkz451</pub-id><pub-id pub-id-type="pmid">31782503</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wigg</surname><given-names>AJ</given-names></name><name><surname>Narayana</surname><given-names>SK</given-names></name><name><surname>Hartel</surname><given-names>G</given-names></name><name><surname>Medlin</surname><given-names>L</given-names></name><name><surname>Pratt</surname><given-names>G</given-names></name><name><surname>Powell</surname><given-names>EE</given-names></name><name><surname>Clark</surname><given-names>P</given-names></name><name><surname>Davies</surname><given-names>J</given-names></name><name><surname>Campbell</surname><given-names>K</given-names></name><name><surname>Toombs</surname><given-names>M</given-names></name><name><surname>Larkin</surname><given-names>M</given-names></name><name><surname>Valery</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hepatocellular carcinoma amongst aboriginal and torres strait islander peoples of australia</article-title><source>EClinicalMedicine</source><volume>36</volume><elocation-id>100919</elocation-id><pub-id pub-id-type="doi">10.1016/j.eclinm.2021.100919</pub-id><pub-id pub-id-type="pmid">34142069</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Boullier</surname><given-names>M</given-names></name><name><surname>Cricks</surname><given-names>Z</given-names></name><name><surname>Ward</surname><given-names>A</given-names></name><name><surname>Naidoo</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Robinson</surname><given-names>K</given-names></name><name><surname>Eisen</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Screening for infection in unaccompanied asylum-seeking children and young people</article-title><source>Archives of Disease in Childhood</source><volume>105</volume><fpage>530</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2019-318077</pub-id><pub-id pub-id-type="pmid">32094246</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Vickerman</surname><given-names>P</given-names></name><name><surname>Douthwaite</surname><given-names>S</given-names></name><name><surname>Nebbia</surname><given-names>G</given-names></name><name><surname>Hunter</surname><given-names>L</given-names></name><name><surname>Wong</surname><given-names>T</given-names></name><name><surname>Ruf</surname><given-names>M</given-names></name><name><surname>Miners</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>An economic evaluation of the cost-effectiveness of opt-out hepatitis B and hepatitis C testing in an emergency department setting in the united kingdom</article-title><source>Value in Health</source><volume>23</volume><fpage>1003</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1016/j.jval.2020.03.014</pub-id><pub-id pub-id-type="pmid">32828211</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirtz</surname><given-names>AL</given-names></name><name><surname>Yeh</surname><given-names>PT</given-names></name><name><surname>Flath</surname><given-names>NL</given-names></name><name><surname>Beyrer</surname><given-names>C</given-names></name><name><surname>Dolan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hiv and viral hepatitis among imprisoned key populations</article-title><source>Epidemiologic Reviews</source><volume>40</volume><fpage>12</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1093/epirev/mxy003</pub-id><pub-id pub-id-type="pmid">29688317</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2002">2002</year><article-title>Hepatitis B</article-title><ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/67746/WHO_CDS_CSR_LYO_2002.2_HEPATITIS_B.pdf;jsessionid=2858FB5335D4BAD2E7C8478256FF0F86?sequence=1">https://apps.who.int/iris/bitstream/handle/10665/67746/WHO_CDS_CSR_LYO_2002.2_HEPATITIS_B.pdf;jsessionid=2858FB5335D4BAD2E7C8478256FF0F86?sequence=1</ext-link><date-in-citation iso-8601-date="2022-11-16">November 16, 2022</date-in-citation></element-citation></ref><ref id="bib130"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Hepatitis B vaccines: WHO position paper</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers/hepatitis-b">https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers/hepatitis-b</ext-link><date-in-citation iso-8601-date="2022-11-16">November 16, 2022</date-in-citation></element-citation></ref><ref id="bib131"><element-citation publication-type="report"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2018">2018a</year><source>Global Status Report on Alcohol and Health Geneva</source><publisher-loc>Switzerland</publisher-loc><publisher-name>World Health Organisation</publisher-name></element-citation></ref><ref id="bib132"><element-citation publication-type="report"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2018">2018b</year><source>Report on the Health of Refugees and Migrants in the WHO European Region</source><publisher-loc>Geneva, Switzerland</publisher-loc><publisher-name>World Health Organisation</publisher-name></element-citation></ref><ref id="bib133"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Prevention of mother-to-child transmission of hepatitis B virus: Guidelines on antiviral prophylaxis in pregnancy</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/978-92-4-000270-8">https://www.who.int/publications/i/item/978-92-4-000270-8</ext-link><date-in-citation iso-8601-date="2022-11-18">November 18, 2022</date-in-citation></element-citation></ref><ref id="bib134"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Hepatitis B</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-b">https://www.who.int/news-room/fact-sheets/detail/hepatitis-b</ext-link><date-in-citation iso-8601-date="2022-03-07">March 7, 2022</date-in-citation></element-citation></ref><ref id="bib135"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2022">2022a</year><article-title>Immunization dashboard</article-title><ext-link ext-link-type="uri" xlink:href="https://immunizationdata.who.int/">https://immunizationdata.who.int/</ext-link><date-in-citation iso-8601-date="2022-11-16">November 16, 2022</date-in-citation></element-citation></ref><ref id="bib136"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2022">2022b</year><article-title>Triple elimination initiative of mother-to-child transmission of HIV, syphilis and hepatitis B</article-title><source>Online</source><ext-link ext-link-type="uri" xlink:href="https://www.who.int/initiatives/triple-elimination-initiative-of-mother-to-child-transmission-of-hiv-syphilis-and-hepatitis-b">https://www.who.int/initiatives/triple-elimination-initiative-of-mother-to-child-transmission-of-hiv-syphilis-and-hepatitis-b</ext-link><date-in-citation iso-8601-date="2022-11-22">November 22, 2022</date-in-citation></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>CM</given-names></name><name><surname>Boudarène</surname><given-names>L</given-names></name><name><surname>Ha</surname><given-names>NT</given-names></name><name><surname>Wu</surname><given-names>O</given-names></name><name><surname>Hawkins</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries</article-title><source>BMC Public Health</source><volume>18</volume><elocation-id>373</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-018-5261-8</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Howell</surname><given-names>J</given-names></name><name><surname>van Gemert</surname><given-names>C</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Seaman</surname><given-names>CP</given-names></name><name><surname>McCulloch</surname><given-names>K</given-names></name><name><surname>Scott</surname><given-names>N</given-names></name><name><surname>Hellard</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Enhancing the hepatitis B care cascade in Australia: a cost-effectiveness model</article-title><source>Journal of Viral Hepatitis</source><volume>27</volume><fpage>526</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1111/jvh.13252</pub-id><pub-id pub-id-type="pmid">31856377</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zewdu</surname><given-names>S</given-names></name><name><surname>Hanlon</surname><given-names>C</given-names></name><name><surname>Fekadu</surname><given-names>A</given-names></name><name><surname>Medhin</surname><given-names>G</given-names></name><name><surname>Teferra</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Treatment gap, help-seeking, stigma and magnitude of alcohol use disorder in rural ethiopia</article-title><source>Substance Abuse Treatment, Prevention, and Policy</source><volume>14</volume><elocation-id>4</elocation-id><pub-id pub-id-type="doi">10.1186/s13011-019-0192-7</pub-id><pub-id pub-id-type="pmid">30658659</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Woodring</surname><given-names>J</given-names></name><name><surname>Rattana</surname><given-names>K</given-names></name><name><surname>Sovannarith</surname><given-names>S</given-names></name><name><surname>Rathavy</surname><given-names>T</given-names></name><name><surname>Cheang</surname><given-names>K</given-names></name><name><surname>Hossain</surname><given-names>S</given-names></name><name><surname>Ferradini</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Sokun</surname><given-names>C</given-names></name><name><surname>Samnang</surname><given-names>C</given-names></name><name><surname>Nagai</surname><given-names>M</given-names></name><name><surname>Lo</surname><given-names>Y-R</given-names></name><name><surname>Ishikawa</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Integrated approach for triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis is highly effective and cost-effective: an economic evaluation</article-title><source>International Journal of Epidemiology</source><volume>48</volume><fpage>1327</fpage><lpage>1339</lpage><pub-id pub-id-type="doi">10.1093/ije/dyz037</pub-id><pub-id pub-id-type="pmid">30879066</pub-id></element-citation></ref></ref-list></back></article>